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The worldwide obesity epidemic is now well recognised; obesity is a major 
problem not least because of the many serious metabolic complications that are 
associated with it. Cbl (Casitas B-lineage Lymphoma) is a receptor tyrosine kinase 
adaptor protein with E3 ubiquitin ligase activity that regulates receptor and non-
receptor tyrosine kinases, resulting in their down-regulation. c-Cbl is a key protein in 
the alternate pathway of insulin signalling to glucose transporter type 4 (GLUT4) 
translocation in 3T3-L1 adipocytes. However, the role of c-Cbl in adipokine 
expression is currently unknown. c-Cbl knockout (Cbl -/-) mice were previously found 
to be more insulin sensitive and resistant to the deleterious effects of a high fat diet 
than control littermates, but the relevant mechanisms remain incompletely explored. 
In this study, the role of c-Cbl signalling was examined in white adipose tissue (WAT) 
of a Cbl -/- mouse model, specifically in glucose and lipid metabolism and adipokine 
production. 
c-Cbl knockout mice exhibited no changes in overall food intake or adiposity. 
However, there was increased ERK activation in WAT of Cbl -/- mice. The adipokine 
profile was altered in WAT of female Cbl -/- mice: leptin and RBP4 were increased, 
whereas adiponectin was reduced. These findings were confirmed in the 3T3L1 
adipocyte cell line expressing shRNAs for c-Cbl. Furthermore, 17β-estradiol increased 
RBP4 mRNA which was attributed to activation of oestrogen receptor alpha (ER-α). 
Regarding diet interventions, fasting decreased circulating concentrations of 
adiponectin in both male and female Cbl -/- mice, while leptin concentrations were 
decreased only in male Cbl -/- mice. However, RBP4 was increased in female Cbl -/- 
following a fast. On the other hand, Cbl -/- mice fed a HFD were protected from diet-
induced insulin resistance. In addition, Cbl -/- mice fed a HFD exhibited an increase in 
xiii 
 
energy expenditure (EE) together with decreased WAT leptin levels in males and 
lower circulating leptin in females. However, under a HFD c-Cbl depletion did not 
protect against increased RBP4 protein content in the liver. 
The findings of this thesis, taken together with the results from other studies, 
highlight the importance of c-Cbl depletion for the prevention and development of 
insulin resistance and T2D. This work is worthwhile not least because it holds promise 
for new treatments by increasing whole-body insulin sensitivity and energy 
expenditure. Further elucidation of the relevant molecular mechanisms will help 
develop a better understanding of the validity of c-Cbl inhibition as a therapeutic 







































1  Introduction 
1.1 Obesity-general overview 
Obesity is now recognised to be a global epidemic and it is estimated that by year 
2030, over 1 billion individuals will be obese worldwide [1, 2]. Obesity is a significant 
risk factor for numerous health problems. It is associated with serious metabolic 
disorders including type 2 diabetes (T2D) and fatty liver disease and is associated with 
chronic low-grade inflammation, atherosclerosis, hypertension, asthma, cancer, 
depression, Alzheimer’s disease, infertility, birth complications, sleep apnoea, 
premature aging and impaired physical ability [2]. The basic cause of obesity is an 
energy imbalance between calories consumed and calories expended. Modern life 
promotes the intake of energy-dense foods that are high in fat, salt and sugars, while 
urbanization and new technologies favour a sedentary life and decreased physical 
activity [3]. According to the World Health Organization (WHO), obesity is defined 
as the body mass index (BMI) >30 kg/m², calculated as the weight in kilograms 
divided by the square of the height in meters [4].  
Obesity resuls in adipose expansion both by adipose cell hyperplasia and 
hypertrophy (Fig. 1) [5, 6]. It is associated with adipose tissue (AT) dysfunction [7]  
which may be mediated by different mechanisms including increased adipocyte cell 
death, hypoxia, altered adipokine profile, remodeling of the extracellular matrix 
(ECM), fibrosis, and inflammation by recruitment and subsequent activation of 
immune cells notably macrophages [7]. Hypertrophy also leads to AT dysfunction, 
which contributes to the development of metabolic syndrome, characterized by several 
metabolic abnormalities, including central (intra-abdominal) obesity, dyslipidaemia, 
hyperglycaemia, hypertension, hyperinsulinemia, insulin resistance and T2D [8-11]. 
Recently, it has been revealed that in mice on high fat diets [12], visceral  AT primarily 
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grows through hypertrophy, whereas a hyperplastic response is predominant for 
subcutaneous AT [12, 13].  
White adipose tissue (WAT) is the primary site of synthesis and storage of 
triglycerides (TGs) supplying fatty acids to other organs during periods of energy 
deprivation. Adipose tissue also secretes adipokines that regulate energy intake and 
metabolism [14]. The expansion of AT in obesity is correlated with increased 
macrophage infiltration and macrophage polarization to a pro-inflammatory 
phenotype (M1) in WAT. This results in an increase in the cytokines secretion such as 
tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which induce insulin 
resistance [9, 15, 16]. 
Identifying potential therapeutic targets to improve insulin sensitivity and 
ameliorate T2D has become a major goal of academic and industry research [17, 18]. 
Over the past decade, several genetically modified mouse models that identify 
promising targets have been described; the latter range from proteins involved in the 
insulin signalling pathway, alterations of genes affecting energy metabolism, and 
transcriptional metabolic regulators [17]. Using genetically manipulated animal 
models, many genes that result in lean phenotypes have been described [19-22]. These 
genes include those that regulate appetite, food absorption, and increased energy 
expenditure in either muscle or adipose tissue. A major advantage of manipulations 
that increase energy expenditure is that they deplete fat stores not only in adipose tissue 
but possibly in other cells that are susceptible to lipotoxic damage, thus providing a 
protective mechanism against the development of insulin resistance and diabetes [18]. 
c-Cbl is a member of Cbl protein family (c-Cbl, Cbl-b and Cbl-c) in mammals. It 
was identified as a key protein in the alternate pathway of insulin signalling to GLUT4 
translocation in 3T3-L1 adipocytes [23, 24], but the role of c-Cbl in adipokine 
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signalling has not previously been studied. c-Cbl knockout mice were found to be more 
insulin sensitive than control wild type mice, but the mechanisms remain incompletely 
understood. The main aim of the present thesis was to determine the contribution of c-











Fig. 1. Adipose tissue expansion via hyperplasia (increased adipocyte cells) and 
hypertrophy (increased volume of existing adipocytes) and the resulting metabolic 








1.2 Diabetes and insulin resistance 
Diabetes is a metabolic disorder caused by insufficient insulin secretion and/or  
insensitivity of tissues to insulin (insulin resistance) [25-28]. There are two main types 
of diabetes: type 1 (T1D) and T2D. Type 1 diabetes is an autoimmune disorder 
characterized by the immune mediated destruction of pancreatic β-cells that leads to a 
deficiency in insulin secretion. It accounts for nearly 10% of all diabetic cases and 
T2D accounts for the remaining 90% of cases [28, 29]. Type 2 diabetes is strongly 
associated with the development of obesity although other factors such as, aging, 
genetic predisposition, and physical inactivity also contribute [28, 30]. The incidence 
of T2D has reached epidemic rates, affecting around 387 million people worldwide. 
The prevalence of T2D diabetes is predicted to double in the next 20 years  [31].  
Insulin resistance is a hallmark of T2D and is defined as the decreased ability of 
tissue to respond to physiological concentrations of insulin [6, 8]. Insulin resistance 
occurs when insulin signal transduction is impaired in target tissues (skeletal muscle, 
liver, adipose tissue and heart) [25, 27]. Defects in insulin action in these tissues, 
particularly in skeletal muscle, reduce the capacity of insulin to decrease blood glucose 
after a meal. The pancreatic β-cell produces more insulin to compensate for the 
impaired insulin sensitivity which progressively leads to β-cell failure and the onset of 
diabetes [32]. Ectopic lipid accumulation in peripheral tissues contributes to the 
development of insulin resistance due to lipotoxicity notably in skeletal muscle [33-
36], where different lipid entities are accumulated including: ceramides, 
diacylglycerol (DAG), and long-chain fatty acyl-CoA levels [37-41]. Whereas, hepatic 
insulin resistance manifests with an increased gluconeogenesis, resulting in high 




1.3 Adipose tissue 
Adipose tissue is considered as one of the most important organs involved in 
metabolic homeostasis [43]. It consists of adipocytes, nerve fibers, connective tissue, 
blood vessels and immune cells [3, 4, 44] and traditionally has been divided into two 
main types [6]: WAT which is energy storing, and brown adipose tissue (BAT) which 
is energy-expending [3, 43]. Recently, brown-like adipocytes were discovered within 
WAT and have been called ‘beige’ or ‘brite adipocytes’ [45-47]. 
1.3.1 White adipose tissue: WAT accounts the majority of body’s fat [13]. It is 
composed mainly of mature adipocytes, but it also contains a stromal vascular fraction 
(SVF) containing preadipocytes, endothelial cells, smooth muscle cells, fibroblasts, 
leukocytes and macrophages (Fig. 2) [10, 44, 48]. White adipose tissue is distributed 
either subcutaneously or viscerally (in the mesentery, omentum and around abdominal 
viscera) [6]. The size of white mature adipocytes is around 25-200 µm [45]. It has long 
been recognized as the main energy storage site where energy is stored in the form of 
TG during energy excess (through the processes of lipogenesis) and released as fatty 
acids (FAs) when the body needs energy (through the processes of lipolysis) [8, 16]. 
Adipose tissue secretes a large number of proteins collectively grouped under the term 
“adipokines”.  
Adipokines act locally as paracrine/autocrine and/or systemically act as endocrine 
mediators [15, 44]. These adipokines influence physiology through different processes 
including appetite control, inflammation, glucose metabolism, adipogenesis, cell 
proliferation and vascularization [15, 44]. Adipokines mediate the crosstalk between 
adipose tissues and other metabolic organs such as liver, muscle, pancreas, peripheral 
and central nervous systems. Dysregulation in adipokine production often leads to 












Fig. 2. Adipose tissue composition. Adipocytes are the main cellular component of 
adipose tissue, and they are crucial for both energy storage and endocrine activity. The 
other cell types that are present are precursor cells (including pre-adipocytes), fibroblasts, 
vascular cells and immune cells such as macrophages and lymphocytes, and these cells 













1.3.2 Brown adipose tissue: BAT constitutes a small fraction of the overall adipose 
tissue mass in the body, but is a key site for heat generation via uncoupling protein-1 
(UCP-1) [52]. In mice, BAT is abundant in the interscapular, cervical, axillary and 
perirenal regions. In humans, depots of BAT have been found in the neck and 
interscapular regions (particularly in newborns) [53], and have been found to gradually 
decrease with age [45]. Brown adipose tissue is characterized by an increased number 
of mitochondria, dense vascularization and multilocular lipid droplets compared to 
WAT which exhibits fewer mitochondria and contains a unilocular arrangement of 
lipids. BAT dissipates energy to produce heat during adaptive non-shivering 
thermogenesis such as cold exposure through UCP-1, a protein uniquely expressed in 
BAT [43, 54-56]. Mitochondria generate adenosine trisphosphate (ATP) through ATP 
synthase, which allows protons to flow down their concentration gradient across the 
internal mitochondrial membrane. In contrast, if the gradient is dissipated through 
UCP1, energy is dissipated as heat (Fig. 3) [56]. Not surprisingly, UCP1 gene 
expression is increased by several stimuli including: cold exposure, adrenergic 
stimulation with β3-agonists, retinoid and thyroid hormones, and cyclic adenosine 





















Fig. 3. UCP1 location and function in the mitochondrial respiratory chain (MRC). 
Numbers I-IV correspond to MRC complexes. ATP-synthase is the fifth complex of the 
MRC. During respiration, protons are pumped through the MRC complexes, and a 
proton gradient is generated. The energy of the proton gradient drives the synthesis of 
ATP by the ATP-synthase complex. UCP1 allows a regulated re-entry of protons into the 
matrix, uncoupling the MRC and, consequently, reducing ATP synthesis and generating 













1.4 Lipogenesis and lipolysis  
White adipose tissue plays a pivotal role in the regulation of lipid metabolism [9]. 
White adipocytes are specialized to store lipids and mobilize fatty acid within the body 
in times of negative energy balance [9, 58]. The regulation of fat accumulation is 
maintained by the balance between lipogenesis (TG synthesis) and lipolysis (TG 
breakdown) [5, 9]. De novo lipogenesis involves the synthesis of FA from acetyl-CoA 
molecules. However, in WAT the main source of FA for esterification into TG comes 
from the diet and the activity of the lipoprotein lipase (LPL) which is the primary 
enzyme responsible for lipolysis of chylomicrons (lipoprotein particles that consist of 
TGs, phospholipids, cholesterol, and proteins) and very low density lipoproteins 
(VLDLs) [59].  
Lipogenesis is the process by which glycerol is esterified with free fatty acid (FFA) 
to form TG (Fig. 4). Dietary fat (triglycerides), when ingested with food, are absorbed 
by the gut and transported in the form of plasma-lipoproteins called chylomicrons. 
Lipids are released from their carrier lipoproteins through the local activity of LPL and 
subsequently split into their constituent FA and glycerol [60]. These are taken up by 
AT where TGs are resynthesized and stored in cytoplasmic lipid droplets. Lipogenesis 
also includes the anabolic process by which TGs are formed in the liver from excess 
glucose. Here fatty acids of various lengths are synthesized by the sequential addition 
of two-carbon units derived from acetyl CoA. Fatty acids generated by lipogenesis in 
the liver, are subsequently esterified with glycerol to form TGs that are packaged, not 
in chylomicrons, but with VLDLs and secreted into the circulation. Once in the 
circulation, VLDLs come in contact with LPL in the capillary beds in the body 
(adipose, cardiac, and skeletal muscle) where LPL releases TGs for intracellular 
storage or energy production [60]. 
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Long chain fatty acyl CoA molecules are subsequently attached to glycerol 
molecule to produce TG. In several sequential steps, firstly through the formation of 
monoacylglycerol (MAG) and later DAG and triacylglycerol (TAG) [61]. Glucose 
serves as substrate for the formation of glyceraldehyde 3-phosphate and is a source of 
acetyl-CoA. Therefore, not surprisingly, a diet rich in carbohydrates stimulates 
lipogenesis in both adipose tissue and liver, leading to elevated postprandial plasma 
TG levels [9, 62, 63]. In addition, glucose increases lipogenesis by stimulating the 
release of insulin and inhibiting the release of glucagon from the pancreas [9, 62]. 
Insulin stimulates lipogenesis by increasing the uptake of glucose by adipocytes via 
recruitment of glucose transporters to the plasma membrane, as well as by inhibiting 
lipolysis. Lipogenesis occurs mainly in adipose tissue, but also in the liver, and to a 
lesser extend in the muscle, heart and pancreas [61]. 
The hydrolysis of TGs involves the breakage of 3 ester bonds to release FAs and 
glycerol (Fig. 4) and occurs during fasting, physical exercise or between meals [8, 10, 
62]; the FFA are then released into circulation and used as an energy source by other 
tissues [62]. This process involves three consecutive steps catalyzed by adipose 
triglyceride lipase (ATGL; also called desnutrin or PNPLA2) that hydrolyzes TAGs 
into to DAGs, the hormone sensitive lipase (HSL) that acts on the DAGs and the 
monoglyceride lipase (MGL) which breaks MAGs to liberate the FA and glycerol (Fig. 
4), [13, 64]. Fatty acids are transported in the circulation bound to albumin and 
conveyed to other tissues for β-oxidation and the generation of ATP [9, 65]. Glycerol 
is released from adipocytes via an aquaporin type of transport molecule and carried to 
the liver to be used as a substrate for gluconeogenesis [62, 65]. Lipolysis can be found 














Fig. 4. The primary metabolic roles of adipose tissue. In the postprandial state, 
insulin-dependent GLUT4 allows the uptake of glucose from the bloodstream into 
adipocytes. Glycolysis occurs and produces G3P, a substrate required for lipogenesis. FA 
carried by very low-density lipoproteins (VLDL) form the liver and chylomicrons from 
the intestine are esterified with G3P to form lipid droplets of triacylglycerols (TAGs). In 
the fasting state and in stress conditions, hormone-sensitive lipase is activated for lipolysis. 
Glycerol produced by lipolysis is transported to the liver, while FFA are transported in 
the circulation to the liver, muscle and other organs to be oxidized. In the circulation, 











Lipolysis in adipocytes is strongly regulated by hormones (Fig. 5A), which include 
catecholamines (adrenaline and noradrenaline) [2, 66] and glucocorticoids. During the 
fasting state, elevated glucocorticoids upregulate desnutrin/ATGL transcription [66, 
67]. Furthermore, catecholamines activate lipolysis via interaction with β-adrenergic 
receptors which are G-protein coupled receptor that activate adenylate cyclase 
increasing cellular cAMP [68]. The latter binds protein kinase A (PKA) to induce HSL 
phosphorylation [58, 68]. HSL is phosphorylated at 5 or perhaps more different serine 
residues [10, 69]. The phosphorylation of HSL on Ser 559/660 is crucial for its 
activation and translocation to the lipid droplet, where HSL catalyzes the hydrolysis 
of diglycerides to monoglycerides.  
Another lipase, adipose triglyceride lipase, carries out the initial cleavage of 
triglycerides to diglycerides and most likely is rate limiting for lipolysis, but it does 
not appear to be regulated directly via PKA phosphorylation [70]. Besides PKA, other 
protein kinases have also been shown to phosphorylate HSL and regulate enzyme 
activity. The list includes extracellular signal-regulated kinase (ERK), glycogen 
synthase kinase-4, Ca2+/calmodulin-dependent kinase II, and AMP-activated kinase 
[60].  
The phosphorylated HSL interacts with the lipid droplet protein perilipin, which 
itself is a target of PKA phosphorylation [60, 71]. The translocation of phosphorylated 
HSL from the cytosol to the lipid droplet is mediated by the phosphorylated form of 
perilipin [60, 70] in WAT where it can access the relevant substrates and stimulate 
lipolysis [58, 60, 68]. Perilipin under basal conditions (non-hormonally stimulated 
state) is not phosphorylated and prevents the binding of HSL to lipid droplets [60]. It 
acts as a protective barrier against lipase activity [70]. In response to β-adrenergic 
stimulation, perilipin is phosphorylated on six consensus serine residues by PKA. 
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Specifically, the phosphorylation of serines 81, 222, and 276 induces the binding of 
HSL to perilipin and access to the lipid droplet [60], and possibly the activation of 
ATGL [70]. Therefore, perilipin, possesses dual functions, both blocking lipolysis in 
the basal state as well as promoting lipolysis upon its phosphorylation [70]. 
In contrast, during the fed state insulin suppresses lipolysis (Fig. 5B) [72]. Insulin 
binds to its receptor in adipocytes and initiates a signalling event that involves the 
activation of the insulin receptor tyrosine kinase, the phosphorylation of insulin 
receptor substrates, the activation of phosphatidylinositol 3-kinase (PI3K), and the 
subsequent production of specific phosphoinositides at the plasma membrane. 
Phosphoinositides then recruit AKT to the plasma membrane via its pleckstrin 
homology (PH) domain, where AKT becomes phosphorylated and activated by two 
upstream kinases. AKT stimulates the translocation of GLUT4 to the plasma 
membrane, thereby promoting the uptake of glucose into the cell [70]. The mechanism 
by which insulin inhibits lipolysis has been proposed to involve the reduction of cAMP 
levels and thus PKA activity (Fig. 5B) [70, 73]. In this model, insulin signalling 
activates phosphodiesterase 3b (PDE3b) via AKT-mediated phosphorylation of 
Ser273. Upon activation by AKT, PDE3b catalyzes the hydrolysis of cAMP to 5’AMP, 









Insulin also suppresses expression of desnutrin/ATGL [67]. Recent studies have 
revealed that lipolysis is dominantly regulated by prostaglandin E2 (PGE2) through 
adipose-specific phospholipase A2 (AdPLA) [74, 75]. AdPLA hydrolyzes the sn-2 
position of phospholipids to generate arachidonic acid (AA), which via 
cyclooxygenase (COX) produces prostaglandin E2 (PGE2), that acts locally by 
binding to inhibitory G-protein (Gαi)-coupled prostaglandin receptor (EP3) present in 
adipocytes, resulting in inhibition of adenylate cyclase (AC) and decreased lipolysis 
(Fig. 5B) [67]. 
In obesity, the lipolytic response is often dysregulated due to insulin resistance; 
basal lipolysis is increased whereas stimulated lipolysis is blunted. Elevated basal 
lipolysis leads to lipid spill over in other peripheral tissues including the liver, skeletal 







Fig. 5. Regulation of lipolysis in adipocytes. (A) Desnutrin/ATGL initiates lipolysis 
by hydrolyzing triacylglycerol (TAG) to diacylglycerol (DAG). Hormone-sensitive lipase 
(HSL) hydrolyzes DAG to monoacylglycerol (MAG) which is subsequently hydrolyzed 
by MAG lipase to generate glycerol and three fatty acids (FAs). The FAs generated during 
lipolysis can be released into the circulation for use by other organs or oxidized within 
adipocytes. During fasting, catecholamines, by binding to Gαs -coupled β-adrenergic 
receptors (β-AR), activate adenylate cyclase (AC) to increase cAMP and activate protein 
kinase A (PKA). PKA phosphorylates HSL resulting in translocation of HSL from the 
cytosol to the lipid droplet. PKA also phosphorylates the lipid droplet associated protein 
perilipin. Additionally, during fasting, glucocorticoids increase the expression of 
17 
 
desnutrin/ATGL. (B) In the fed state, insulin binding to the insulin receptor (IR) results 
in decreased cAMP levels and decreased lipolysis. Insulin also suppresses expression of 
desnutrin/ATGL. Reproduced from [67]. 
 
1.5 WAT as an endocrine organ 
Adipose tissue releases a wide variety of bioactive peptides or proteins, called 
adipokines or adipocytokines [11]. Adipokines have multiple functions and contribute 
to many physiological and pathophysiological processes through autocrine and 
paracrine mechanism of action [77, 78], including: appetite, inflammation, insulin 
sensitivity and energy homeostasis [4, 11]. Some adipokines have anti-diabetic effects 
such as adiponectin and visfatin and improve insulin sensitivity, while others inhibit 
insulin signalling and induce insulin resistance for example TNF-α, IL-6 and retinol 
binding protein-4 (RBP4) [4]. Different WAT depots display different adipokine 
profiles that cause inflammation and insulin resistance in obese rodent and human [11, 
16]. Subcutaneous WAT displays a lower proinflammatory profile than visceral WAT 
[79]. Also, clinical studies have demonstrated that FFA, C-reactive protein (CRP), IL-
6 and TNF-α circulate at higher concentrations in patients with greater visceral fat 
[80]. Adipokine dysregulation has been considered key in the development of obesity 
and metabolic syndrome [8, 11, 16, 49].   
In obesity, adipocytes and AT macrophages exhibit enhanced secretion of pro-
inflammatory cytokines that cause a systemic low-grade inflammation and 
subsequently obesity-related complications [6, 13, 29]. Obese subjects have high 
plasma levels of leptin, although its action are suppressed due to leptin resistance [6]. 




1.5.1 Adiponectin: is a 244 amino acid residue, 30 kDa protein, that is predominantly 
produced by WAT and, at lower concentrations BAT [81, 82]. It was discovered in the 
mid-1990 by four independent  research groups and according has multiple names: 
adipocyte complement-related protein of 30 kDa (Acrp30), adipose most abundant 
gene transcript 1 (apM1), gelatin-binding protein (GBP28) and Adipo Q [77, 81, 83, 
84]. Adiponectin monomer is composed of an N-terminal collagen-like domain and a 
C-terminal globular domain. However, adiponectin circulates as trimers, hexamers, 
and high molecular weight (HMW) multimers [85]. It acts via two receptors, AdipoR1 
and AdipoR2 [77]. AdipoR1 is expressed mainly in skeletal muscle, whereas AdipoR2 
is expressed most abundantly in liver in both mice and human [83, 86]. Structurally 
these two receptors share 67% of identity in their amino acid sequence, and are highly 
conserved, displaying 95% of identity between human and mice [81]. AdipoR1 has 
low affinity for full length adiponectin (fAd) and high affinity for the globular domain 
(gAd), which is a fragment of fAd, generated by proteolytic cleavage at amino acid 
110. In contrast, AdipoR2 has intermediate affinity for both forms of adiponectin [81]. 
Adiponectin activates 5’-adenosine monophosphate-activated protein kinase (AMPK) 
via AdipoR1 and peroxisome proliferator-activated receptor alpha (PPAR-α) via the 
AdipoR2 [87], which are essential for glucose uptake, fatty acids oxidation [81, 86, 
87] and oxidative stress [87]. In muscle, adiponectin mediated activation of AMPK 
inhibits acetyl coenzyme A carboxylase and stimulates PPAR-α. This facilitates 
entrance of FA into the mitochondria for their oxidation [8, 83, 88]. In the liver, 
adiponectin inhibits hepatic glucose production by suppressing both glycogenolysis 
and gluconeogenesis. Suppression of glucose-6-phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK) enzymes, inhibits glycogenolysis and 
gluconeogenesis [89, 90].  
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In addition, adiponectin has potent anti-inflammatory properties [16] and its 
expression is reduced by pro-inflammatory cytokines such as TNF-α and IL-6 [16, 89, 
91]. Its circulating levels are positively correlated with insulin sensitivity [84, 91], and 
negatively with BMI [11]. Administration of exogenous adiponectin or overexpression 
in transgenic mice improves insulin sensitivity. Adiponectin deficient mice 
(Adiponectin/ACRP30 KO) developed HFD-induced inflammation and insulin 
resistance in muscle and adipose tissue [16, 92]. Also Adipo R1/R2 double-KO mice 
develop insulin resistance in the liver [11, 93].  
1.5.2 Leptin: is a 16 kDa peptide hormone, which is highly expressed in WAT [6] but 
is also found in a variety of tissues including placenta, mammary gland, ovary, skeletal 
muscle, stomach, pituitary gland, and lymphoid tissue [94]. Its structure is similar to 
that of a family of pro-inflammatory helical cytokines, including interleukin-2 (IL-2) 
and IL-6 [16]. Leptin was first identified in 1994 [95] as the product encoded by the 
obese gene (ob), the murine homologue of the human gene LEP [77]. It is one of the 
most important signals for the regulation of food intake and energy homeostasis. 
Hypothalamic as well as brain stem nuclei play a critical role in integrating the 
information on absorbed food, on the amount of energy stored in the form of fat and 
on blood glucose levels to regulate feeding, energy storage, or expenditure [95].  
Leptin exerts its effects by binding to specific leptin receptors (LepRs) located 
throughout the central nervous system (CNS), as well as elsewhere. Four alternatively 
spliced isoforms of LepR have been identified in humans. The long isoform of leptin 
receptor (LepRb) is highly expressed in the hypothalamus and other brain regions, 
where it regulates energy homeostasis and neuroendocrine function, and considered as 
the main leptin receptor [96]. The short isoforms of LepR are thought to mediate the 
transport of leptin across the blood-brain barrier [97].  
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Leptin inhibits appetite [8] by acting on specific hypothalamic nuclei [77, 78, 82]. 
In the arcuate nucleus (ARC), leptin interacts with a complex neural circuit to control 
food intake by activating anorexigenic neurons that produce pro-opiomelanocortin 
(POMC) and cocaine- and amphetamine-regulated transcript (CART), and inhibiting 
orexigenic neurons that synthesize agouti-related peptide (AgRP) and neuropeptide Y 
(NPY) [11, 77, 82, 98, 99].  
Leptin deficiency correlates with hyperphagia, insulin resistance, hyperlipidaemia 
and impaired thermogenesis [83]. During fasting, circulating leptin levels decline 
rapidly. The fall in leptin stimulates the expression of AgRP and NPY and suppresses 
POMC and CART, thereby increasing food intake and decreasing energy expenditure 
[98, 99]. Leptin also acts on ventromedial hypothalamic (VMH) neurons that express 
the transcription factor steroidogenic factor 1 (SF-1). More recently, brain-derived 
neurotrophic factor in the VMH has been linked to the effect of leptin on feeding and 
energy balance. Mice with SF-1 deletion in the VMH are susceptible to diet-induced 
obesity, associated with impaired thermogenesis [94], whereas leptin deficient 
Lepob/Lepob and leptin receptor deficient Leprdb/Leprdb mice exhibit marked 
hyperphagia, obesity and insulin resistance [16]. Exogenous administration of leptin 
to Lepob/Lepob mice restores insulin sensitivity and reduces obesity [16]. However, in 
Leprdb/Leprdb mice the signalling form of the leptin receptor is deleted, and these mice 
are consequently unresponsive to exogenous or endogenous leptin [100].  
Leptin also plays a pivotal role in the regulation of glucose homeostasis, 
independently of its effects on the central nervous system [8]. It directly increases 
glucose uptake and fatty acid oxidation in skeletal muscle. It increases insulin-like 
growth factor binding protein-2 (IGFBP-2) mRNA, a protein that is reduced in obesity 
and type 2 diabetes, in human skeletal muscle through both signal transducer and 
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activator of transcription-3 (STAT3) and PI3K, in parallel with enhanced insulin 
signalling [101]. It also induces an inflammatory response via its full-length isoform 
receptor (LepRb) and janus kinase 2 (JAK 2) as well as activation of signal transducer 
and STAT3 pathway [16]. It activates monocytes to produce pro-inflammatory TNF-
α and IL-6 and stimulates the production of CC-chemokine ligands (CCL3, CCL4 and 
CCL5) by macrophages [16].  
In obese humans or mice, leptin resistance results in the accumulation of  
triglycerides despite the high circulating levels of leptin [10, 89]. In fact, the leptin-
signalling pathway activates suppressor of cytokine signalling-3 (SOCS-3), which 
might inhibit insulin signalling [89, 102]. 
1.5.3 TNF-α (tumor necrosis factor-α): is a cytokine with both proinflammatory and 
immunoregulatory roles [103]. It was first discovered in 1975 by Carswell et al. [104] 
and named after the discovery of its cytotoxicity to tumor cells in 1984 [105]. TNF-α 
is produced mainly by monocytes, macrophages [16, 51] and other immune cell types 
such as T lymphocytes, natural killer (NK) cells and neutrophils [106]. Rodent 
adipocytes also produce TNF-α but this is much reduced in humans [89]. TNF-α has 
pleiotropic effects on different cell types and plays an important role in the 
pathogenesis of many chronic and acute inflammatory conditions, including trauma, 
sepsis, infection and rheumatoid arthritis [107, 108]. TNF-α also has essential 
immunoregulatory functions as it increases the levels of C-reactive protein (CRP) and 
other  cytokines and adhesion molecules, thus coordinating acute phase reactions 
which can lead to fever, anaemia, anorexia and cachexia [109].  
TNF-α mediates its actions via two distinct types of receptors TNF-α receptor 1 
(TNFR1, also called p55 or p60) and TNF-a receptor 2 (TNFR2, also called p75 or 
p80). Two bioactive forms of TNF-α exist, a transmembrane form and a secretory 
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form; transmembrane TNF-α is converted to the secretory active form through 
proteolytic cleavage by the metalloprotease, TNF-α-converting enzyme (TACE) 
[106]. TNF-α has an important role in inflammatory and autoimmune diseases [51]. It 
contributes to the pathophysiology of obesity and insulin resistance [8, 89] and its 
expression increases in metabolic disorders in both humans [8] and rodents [16].      
TNF-α stimulates the phosphorylation of insulin receptor substrate (IRS) at Ser-
307 which is associated with insulin resistance in skeletal muscle and adipose tissue 
[16, 51] and suppression of insulin-induced IRS1 tyrosine phosphorylation and 
activation of downstream targets  [16, 110]. Treatment of AT with TNF-α causes 
insulin resistance, whereas ablation of TNF-α or its receptors increases insulin 
sensitivity in obese animals [8]. Nielsen et al. [111] found that TNF-α infusion into 
healthy subjects caused peripheral insulin resistance by interfering with AKT substrate 
phosphorylation, particularly inhibiting GLUT4 translocation to the cell membrane in 
both muscle and adipose tissue [111]. However, reduction in body weight in obese 
subjects and rodents is associated with a reduction in TNF-α expression [51].  
1.5.4 IL-6 (interleukin-6): is a multifunctional cytokine with well-known pro- and 
anti-inflammatory properties [112]. IL-6 was cloned in 1986 by Kishimoto’s group 
[113] as a B-cell stimulatory factor [114]. It is a 184 amino acid residue glycosylated 
protein [115] that can be secreted by both immune cells (B-cells, T-cells, macrophages, 
microglia) and non-immune cells (adipocytes, muscle cells, endothelial cells, 
fibroblast and neurons) [114]. IL-6 induces intracellular signalling pathways through 
binding to a specific receptor, interleukin-6 receptor (IL-6R), which is a type I 
transmembrane protein [115] and only expressed on hepatocytes, leukocyte-like 
neutrophils and T cells [112, 116]. IL-6R lacks the intrinsic capacity for signal 
transduction [114]. Therefore, signalling is induced though IL-6/IL-6R complex 
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binding to a second transmembrane receptor B-subunit glycoprotein 130 (gp130), 
which serves as a signal transducer for IL-6 [115] and can be found ubiquitously in all 
cell types [112]. In the absence of IL-6R, IL-6 shows no binding affinity for gp130. 
Therefore, only cells which express IL-6R can respond to IL-6 [115]. In a second 
pathway, trans-signalling, IL-6 binds to soluble forms of IL-6R (sIL-6R), and IL-
6/sIL-6R complexes can activate all cells due to the uniform expression of gp130. 
Importantly, several soluble forms of gp130 (sgp130) are found in the circulation and 
act as natural inhibitors of IL-6 trans-signalling. Most pro-inflammatory roles of IL-6 
have been attributed to the trans-signalling pathway, whereas anti-inflammatory and 
regenerative signalling, including the anti-bacterial acute phase response of the liver, 
is mediated by IL-6 classic signalling [112].  
IL-6 abundance correlates positively with adiposity, whereas body weight loss 
leads to a decline in IL-6 and improved insulin sensitivity [44, 51]. There is also a 
positive relationship between IL-6 in AT and circulating C-reactive protein, another 
marker of inflammation [44, 89]. Both IL-6 and C-reactive protein are associated with 
development of T2D [44]. However, conflicting data exist regarding the correlation 
between IL-6 and insulin resistance. It was reported that IL-6 decreases insulin-
dependent hepatic glycogen synthesis and glucose uptake in adipocytes, whereas it 
increases glucose uptake and glycogen synthesis in myotubes [95]. The effects of IL-
6 on hepatic glucose production is controversial [117, 118]. Kim et al. [117] 
demonstrated that infusion of IL-6 blunted the ability of insulin to suppress hepatic 
glucose production in mice. In contrast, Inoue et al. [118] reported that intraventricular 
insulin administration resulted in IL-6-mediated inhibition of hepatic gluconeogenesis. 
In hepatocytes, IL-6 inhibits insulin-stimulated metabolic actions by inducing SOCS-
3 expression [51, 119]. Also, it has been shown that administration of IL-6 in mice 
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suppresses the ability of insulin to inhibit glucose production in the liver [51, 117]. In 
adipose tissue, however, inhibition of IL-6 signalling via ablation of c-JUN N-terminal 
kinase (JNK1), protects against the development of insulin resistance by modulating 
the expression of hepatic SOCS-3 [51, 120].  
1.5.5 RBP4 (retinol-binding protein 4): is a 21 kDa protein, that belongs to the 
lipocalins family that binds small hydrophobic molecules [121]. It is a specific 
transporter for retinol (Vitamin A) in the circulation. It carries hydrophobic retinol 
from the liver, where the majority of dietary retinoids are stored as retinyl esters in 
stellate cells [121]. Adipocytes also store substantial amounts of retinyl esters [122]. 
The lipid-soluble vitamin retinol is delivered to target cells mainly by two distinct 
mechanisms: as retinyl esters incorporated in lipoproteins (primarily chylomicrons) or 
bound to the RBP4 [123]. RBP4 is synthesized mainly by hepatocytes [124], but its 
mRNA can be expressed in other extra-hepatic tissues including adipose tissue, lung 
and kidney [121].  
RBP4 expression in adipocytes is inversely correlated with that of GLUT4  [16]. 
The role of RBP4 in obesity and insulin resistance was first discovered in genetically 
modified mice by Khan’s group [125, 126]. They found that adipose-specific GLUT4 
knockout mice (adipose GLUT4-/-) developed insulin resistance in liver and muscle 
[125]. In contrast, adipose-specific overexpression GLUT4 mice showed an increased 
in glucose clearance capacity [126]. Later Yang et al. [127] showed that adipose 
GLUT4-/- mice displayed an increased in RBP4 gene expression, and conversely RBP4 
was reduced in mice overexpressing GLUT4 selectively in adipose tissue [126].  
RBP4 bound to retinol (named holo-RBP4) is released from hepatocytes and binds 
transthyretin (TTR) in serum to form a complex that prevent renal filtration and 
elimination [121, 123]. In target cells, RBP4 binds to its receptor, STRA6 (stimulated 
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by retinoic acid-6), after dissociation from the TTR complex [123]. STRA6 is 
expressed in numerous tissues including skeletal muscle, brain, retina, testis and 
placental endothelial cells, but  it is not expressed in liver or intestine [122]. A second 
receptor  for RBP4 was identified in 2013 by Alapatt and his group [122], known as 
RBPR2 (RBP4 receptor-2). RBPR2 is mainly expressed in liver and small intestine 
and in adipocytes of obese mice [122], but also it is highly expressed in dendritic cells 
and lipopolysaccharide (LPS)-treated macrophages [121].  
Increased secretion of RBP4 derived from WAT decreases glucose uptake in 
muscle by inhibiting phosphorylation of PI3K and IRS-1. In contrast in the liver, RBP4 
has no effect on PI3K but it increases the expression of the gluconeogenic enzyme 
PEPCK, thereby increasing glucose output [10, 128, 129]. Many studies [129-132] 
have found a positive correlation between plasma concentrations of RBP4 and the 
severity of insulin resistance in obese/T2D and in non-obese subjects with a strong 
family history with T2D [89, 133], but others have not [126, 134-138]. Injection of 
recombinant RBP4 into normal mice, or transgenic overexpression of human RBP4, 
induced insulin resistance. In contrast, insulin sensitivity was improved in mice with 











1.6 Insulin action on glucose metabolism 
Insulin is a peptide hormone which has strong anabolic effects. It is secreted from 
β- cells of the islets of Langerhans in response to elevated blood glucose [2, 4, 44]. It 
has a vital role in the regulation of glucose and lipid metabolism, adipogenesis and 
energy expenditure. It coordinates the processes associated with glucose uptake, 
lipolysis and gluconeogenesis [140] in multiple target tissues including liver, muscle, 
adipose tissue and heart [25, 27]. Several factors stimulate the secretion of insulin by 
the pancreas including a rise in plasma glucose, amino acids and several 
gastrointestinal hormones named incretins (glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP)) [44].  
Adipocyte growth, differentiation and energy homeostasis is regulated by insulin 
[2]. Energy homeostasis is controlled by insulin through the regulation of lipogenesis, 
FA uptake, protein synthesis and inhibition of lipolysis (Fig. 6) [2, 4]. Insulin impacts 
FA metabolism by increasing LPL activity in adipocytes which leads to increase FFA 
uptake that in turn enhances TGs synthesis [4, 44].  
In the liver, insulin stimulates glycogen synthesis through a process called 
glycogenesis and inhibits hepatic glucose output by inhibiting glycogenolysis [44].  
In adipose tissue, heart and skeletal muscle, insulin is known to activate several 
protein cascades that lead to an increase in glucose uptake. It stimulates the 
translocation of facilitative GLUT4 from an intracellular store to the cell surface, 
which facilitates glucose uptake and reduces circulating blood glucose levels [26, 141-
143]. GLUT4 has a key role in the regulation of whole-body glucose homeostasis [141, 
144, 145]. After a meal about 90% of glucose clearance occurs in skeletal muscle, 
whereas only 10% in adipose tissue [144].  
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In the absence of insulin, around 95% of cellular GLUT4 localizes to intracellular 
compartment(s) [146] and only about 5% of the total GLUT4 pool can be found at the 
cell surface [144, 147]. Individuals with insulin resistance and T2D exhibit defective 
insulin-stimulated GLUT4 translocation and consequently much effort has gone into 
defining the trafficking of GLUT4 in adipocytes and muscle cells [144].  
 
Fig. 6. Function of insulin and pathology underlying insulin resistance and 
insufficient insulin secretion. FFA = free fatty acids, → = stimulation, Ʇ = inhibition 







1.7 Insulin signalling pathways 
The insulin receptor (IR) belongs to the receptor tyrosine kinase (RTKs) family of 
receptors that includes the insulin like growth factor-1 receptor (IGF-1R), the insulin 
receptor-related protein (IRR), the epidermal growth factor receptor (EGFR) and the 
platelet-derived growth factor receptor (PDGFR) [149]. The IR has two splice 
isoforms IR-A and IR-B [150]; IR-A has a higher affinity for insulin-like growth 
factors (IGFs), especially for IGF-II, whereas IR-B isoform binds predominantly to 
insulin [150, 151]. IR-A is the predominant IR isoform expressed in cancer cells and 
fetal tissues [150, 152]. IR-B is expressed in differentiated insulin-responsive tissues 
[152]. Both receptors contain 2 alpha (α) and 2 beta (β) subunits bound with disulphide 
bonds. The extracellular α subunit of each hemireceptor contains the ligand binding 
sites, whereas β subunits span the cellular membrane and the intracellular domain 
contains the tyrosine kinase activity [140, 150, 153]. IR is ubiquitously expressed in 
all tissues [140].  
Binding of insulin to the α-subunit of the receptor leads to a conformational change 
in the protein which activates the tyrosine kinase domain. The activated IR kinase 
domain phosphorylates several proximal adaptor proteins including: the IRS1-4 family 
of proteins, the  growth factor receptor binding protein 2 (Grb2)-associated binding 
protein 1 (Gab-1), adaptor protein APS with src homology 2 (SH2) and PH domains, 
and the proto-oncogene Cbl [4, 6, 29, 149]. Phosphorylation of these proteins activates 
at least three different pathways: PI3K-AKT/protein kinase B (PKB) pathway, the Cbl/ 
Cbl associated protein (CAP) pathway and the Ras-mitogen-activated protein kinase 
(MAPK) pathway (Fig. 7) [6, 29].  
 


















Fig. 7. Insulin signalling pathways in adipose tissue. The red arrows indicate up-
regulation (↑) or down-regulation (↓) in response to PI3K-AKT/PKB signalling pathway, 











1.7.1 MAPK- signalling pathway: The Rat sarcoma (Ras) – mitogen-activated 
protein kinase (MAPK) also termed ERK signalling pathway, comprises a sequence 
of intracellular cytosolic serine threonine kinases (Fig. 8). Activation of this pathway 
starts with the phosphorylation of IRS1-4 proteins by the insulin and IGF receptor 
which leads to the recruitment of the adaptor protein Grb2 to Tyr-phosphorylated IRS 
[29, 149]. In turn this allows the recruitment of the protein son-of-sevenless (SOS), 
which is a guanine nucleotide exchange factor. The complex Grb2–SOS causes the 
conversion of guanosine diphosphate Ras-GDP to Ras-GTP (guanosine triphosphate). 
The activated Ras-GTP recruits and activates the protein kinase Raf-1, which induces 
phosphorylation of two protein serine threonine kinases named (MEK)-encoding 
genes, MEK1 and MEK2 on residues Ser218 and Ser222. Then MEK1 and MEK2 
coordinate the phosphorylation and activation of ERK1/2 through threonine and 
tyrosine residue phosphorylation. ERK1 is phosphorylated by MEK1 and MEK2 on 
Thr202 and Tyr204 whereas ERK2 on Thr185 and Tyr187 [149].  
ERK phosphorylates and regulates the activity of cytosolic proteins and of various 
nuclear transcription factors that are involved in cell growth, cell survival and 
differentiation [4, 6, 29, 142, 149, 154-156]. In mammalian cells, there are three well-
known MAPK cascades: the ERK1/2, JNK1/2/3 and the p38 MAPK α, β, δ, and γ 
pathways. ERK, JNK and p38 proteins are grouped according to their activation motif, 
structure and function. In addition to insulin, ERK1/2 are activated in response to other 
growth factors including epidermal growth factor (EGF), platelet-derived growth 
factor (PDGF) and fibroblast growth factor (FGF), and also pro-inflammatory stimuli 
for example TNF-α, while JNK1/2/3 and p38 MAPK α, β, δ, and γ are activated by 
cellular and environmental stresses (oxidative or heat stress) in addition to pro-















Fig. 8. MAPK signalling pathway. The Ras-mitogen-activated protein kinase pathway 
leads to the activation of genes which are involved in cell growth, thereby promoting 














1.7.2 The PI3K–AKT/PKB pathway: The phosphatidylinositol 3-kinase (PI3K) is a 
ubiquitous enzyme first discovered in 1984 [159]. Activation of the PI3K-AKT/PKB 
pathway is a key mechanism regulating cell metabolism and cell survival. When this 
pathway is activated by insulin in adipocytes it regulates glucose transport and 
metabolism and stimulates protein and lipid synthesis [149].  
PI3K signalling is initiated following insulin receptor-mediated phosphorylation 
of IRS1-4 proteins (Fig. 9) [4, 149, 159]. The main isoforms of IRS are IRS-1 in 
skeletal muscle and adipocytes, and IRS-2 in liver [154]. Upon phosphorylation of IRS 
on tyrosine residues in the cytosol, IRS-1 acts as a docking site for SH2 proteins 
including the regulatory domain of PI3K named p85. Binding of p85 to IRS-1 results 
in its recruitment to close proximity of the IR and to its subsequent phosphorylation at 
tyrosine residues by the insulin receptor. This phosphorylation helps recruit the 
catalytic subunit p110 and activates the enzyme. Activated PI3K catalyses the 
synthesis of phosphoinositol second messengers including: phosphatidylinositol 
(3,4,5) triphosphate (PI (3,4,5) P3) from biphosphate (PI (4,5) P2) in the plasma 
membrane [4, 144, 149, 159-161]. PIP3 activates the serine/threonine of 
phosphoinositide dependent kinase 1 (PDK1) which contains a PH domain [149, 159]. 
Binding of PIP3 to the PH domain alters the conformation of the protein and activates 
the enzyme. PDK1 then phosphorylates and activates two main downstream kinases, 
PKB also named AKT and an isoform of protein kinase C, PKC zeta (PKCζ). Binding 
of PIP3 to the PH domain of AKT facilitates its recruitment to the plasma membrane 
and causes a conformational change in the protein that exposes and facilitates its 
phosphorylation at Thr308 by PDK1. Phosphorylation of Thr308 is sufficient and 
required for the activation of AKT. However, for maximal activation, further 
phosphorylation is required at Ser473, which is catalysed by the enzyme 
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phosphoinositide dependent kinase 2 (PDK2), also known as mTORC2 (for 
mammalian target of rapamacyin complex 2) [149, 159].  
AKT is a serine threonine kinase that phosphorylates several intracellular targets. 
Among them the AKT substrate of 160 kDa (AS160) also known as TBC1 domain 
family member 4 (TBC1D4), TBC (Tre-2, BUB2, CDC16) domain-containing 
protein, which is a protein with GAP activity that targets several Rab GTPases [16, 
162]. These Rabs are small G-proteins that in their GTP-bound form participate in 
vesicle movement and fusion [163], notably Rab8 and Rab14 in skeletal muscle and 
Rab10 in adipocytes, which are components in the GLUT4 storage vesicles (GSVs) 
[164]. AKT also phosphorylates and inactivates the enzyme glycogen synthase kinase-
3 (GSK3) resulting in activation of glycogen synthase and glycogen synthesis in 
muscle and liver [16, 162].  
While there is compelling evidence demonstrating the importance of the PI3K-
dependent pathway for the translocation of GLUT4 and activation of glucose uptake 
[4, 159], some data indicate that the activation of PI3K is not sufficient [165]. A non-
PI3K-dependant pathway was reported to contribute to GLUT4 translocation in 






















Fig. 9. The PI3K/AKT signalling pathway. The insulin receptor simultaneously 
initiates the PI3K-dependent signalling cascade by phosphorylating IRS proteins, thus 
producing docking sites for the recruitment and activation of PI3K. This kinase converts 
PIP2 to PIP3, which serves as a platform for the recruitment of PDK1 and AKT. When 
at the plasma membrane, AKT is phosphorylated by PDK1 and mammalian target of 
rapamycin complex 2 (mTORC2), which results in AKT activation. AKT promotes GSV 
exocytosis by phosphorylating and inactivating two GTPase-activating proteins (GAPs), 
AS160 and the RAL–GAP complex (RGC, consisting of a regulatory subunit (RGC1) and 
a catalytic subunit (RGC2)), which regulate small GTPases that are involved in GLUT4 











1.7.3 Cbl-CAP signalling pathway: Casitas b-lineage lymphoma (Cbl) is an adaptor 
protein with an intrinsic E3 ubiquitin ligase activity that plays a role in regulating 
receptor tyrosine kinase signalling [22, 166, 167] and was identified as necessary for 
insulin-mediated activation of glucose transport in 3T3L1 adipocytes independent of 
the PI3K/AKT pathway [23, 24, 168, 169]. Cbl is recognized as a 120-kDa 
cytoplasmic protein rapidly phosphorylated following the stimulation with insulin and 
other growth factors [23].  
The discovery of Cbl began with studies of haematopoietic tumors in mice infected 
with the Cas-Br-M retrovirus [166] in 1989 by Langdon et al. [170-172]. The causative 
retrovirus was called Cas NS-1 and its oncogene named viral Cbl (v-Cbl), for Casitas 
B lineage lymphoma [166]. Following the cloning of c-Cbl genes in mice it was 
revealed that  v-Cbl encoded only the first 355 amino acids of 913 amino acids of the 
complete c-Cbl protein [166]. 
Mammalian Cbl proteins are encoded by three genes known as c-Cbl, Cbl-b and 
Cbl-c/Cbl-3 (Fig. 10) [172-175]. c-Cbl and Cbl-b are highly related in their primary 
structure and their domain architecture. In contrast, Cbl-c/Cbl-3 represents a shorter 
isoform that lacks some of the key domains and motifs in its C-terminal [176, 177]. 
Cbl-3/Cbl-c isoform is expressed only in the skin, while c-Cbl and Cbl-b are 
ubiquitously expressed in mammalian cells with c-Cbl being the predominant isoform 
in mature adipocytes [23, 166, 172]. All three members of Cbl family share a highly 
conserved region in their N-terminal domain which includes a TKB (tyrosine-kinase-
binding) domain and a small linker region and RING (Really Interesting New Gene) 
finger domain [172-174, 178].   
The TKB domain is composed of a four-helical bundle (4H), a calcium binding EF 
hand and variant SH2 domain [172, 178]. The TKB domain binds phosphotyrosine 
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residues in multiple protein tyrosine kinases (PTKs) such as ZAP-70 (70 kDa zeta-
chain associated protein), Syk (spleen tyrosine kinase) and Src (SH2) [179]. The RING 
finger domain and the linker region together facilitate binding to E2 ubiquitin-
conjugating enzymes and both of these domains are necessary for the E3 ubiquitin 
ligase activity [174, 178].  
The C-terminal part is much less conserved among Cbl proteins. Cbl-c possesses 
a relatively short region carboxyl to the RING finger (RF) domain. c-Cbl and Cbl-b 
contain multiple protein-protein interactions motifs including a proline-rich domain 
that binds with a number of SH2- and SH3-domain. These domains contain proteins 
such as Src kinase and the Grb2 adaptor protein; a ubiquitin associated-leucine zipper 
motif at the C-terminus and several tyrosine residues that are phosphorylated by PTK 
upon cytokine and/or growth factor stimulation [175, 178].  
The process of ubiquitylation involves multiple steps and requires three enzymes 
at least for successful action (Fig. 11). The three enzymes are known as E1, E2 and E3 
[173]. The first, E1, is the ubiquitin-activating enzyme that recruits ubiquitin. The 
second, E2, is the ubiquitin-conjugating enzyme that transfers ubiquitin to the targeted 
protein. The third, E3, is the ubiquitin ligase that acts as a scaffold protein and interacts 
with E2 to transfers ubiquitin to the target protein [174]. Cbl specifically transfers 





Fig. 10. Structure of Cbl family proteins. Domain structures of Cbl family proteins are 
illustrated. Major tyrosine phosphorylation sites in c-Cbl are indicated. Molecular 
interactions of c-Cbl with cytokine receptors and other signalling molecules are also 
displayed on top. Reproduced from [175]. 
 
 
Fig. 11. A schematic of ubiquitylation process in Cbl protein. Cbl proteins mediate 
ubiquitylation (Ub) and the downregulation of receptor tyrosine kinases (RTKs). Whether 
Cbl proteins associated with activated complexes are degraded in lysosomes or 






The Cbl signalling pathway (Fig. 12) is initiated by the recruitment of Cbl to the 
proximity of the insulin receptor and its phosphorylation at tyrosine residues. 
Recruitment is facilitated by the adaptor protein APS. This protein is phosphorylated 
by the insulin receptor at tyrosine 618. Upon phosphorylation APS recruits c-Cbl into 
proximity with the insulin receptor where Cbl is then phosphorylated at tyrosines 700 
and 774 [23]. c-Cbl is bound to Sorbs1 also known as Cbl associated protein (hereafter 
named CAP). CAP contains three src homology-3 (SH3) domains in its C-terminus 
and a region of homology to the gut peptide sorbin (SoHo domain) in its N-terminus 
[23]. CAP is recruited with Cbl via its SH3 domain at the C-terminus and another 
direct interaction with APS through its N- and C-terminal SH3 domains [149] that 
allows the association of complex with the caveolae resident protein flotillin. This 
interaction facilitates the subsequent recruitment of additional downstream proteins. 
Among them the complex recruits the adaptor protein CrK2 and guanyl nucleotide 
exchange factor (C3G). C3G is a guanosine triphosphate exchange factor (GTP) 
protein that regulates the activity of the small GTP binding protein TC10 (also called 
Rho family GTPase). TC10- is located in caveolae microdomain [23, 140, 149, 181] 
of the plasma membrane of adipocytes. C3G activates TC10 [149, 181] which in turn 
interacts with multiple downstream proteins that regulate GLUT4 vesicle exocytosis. 
In this context, the best understood molecules at the moment include CDC42 
interacting protein 4 (CIP4) which forms a stable complex with RAB GEF GAPEX5, 
and the RAB5 family GTPases that are involved in endosomal traffic of membranes 
and facilitate  translocation and fusion of internal vesicles containing GLUT4 with the 













Fig. 12. The Cbl-CAP signalling pathway. The APS (adaptor protein with pleckstrin 
homology (PH) and Src homology 2 (SH2) domains)–insulin signalling cascade is initiated 
when the activated insulin receptor recruits the adaptor proteins APS, c-CBL and c-CBL-
associated protein (CAP). Insulin receptor-catalysed Tyr phosphorylation of c-CBL in 
turn facilitates the recruitment of the adaptor protein CRKII and the guanine nucleotide 
exchange factor (GEF) C3G to the plasma membrane, where C3G activates the small 
GTPase TC10. GTP-bound TC10 interacts with the exocyst complex, thereby creating 
targeting sites for the glucose transporter type 4 (GLUT4) storage vesicle (GSV) at the 
plasma membrane. TC10 also interacts with CDC42‑interacting protein 4 (CIP4), which 
is associated with the RAB5 and RAB31 GEF GAPEX5. Translocation of GAPEX5 to 
the cell surface modulates the activation state of its target small GTPases, which are 










Hypothesis and aims of the thesis 
The overall hypothesis for this thesis is that c-Cbl deficiency impacts on white adipose 
tissue biology, affecting insulin sensitivity, glucose and lipid metabolism and 
adipokine production. 
The following specific objectives address the hypothesis:  
1. To determine the changes in adiposity, adipose tissue morphology and lipid 
content in c-Cbl knockout (Cbl -/-) compared with wild type (Cbl +/+) mice.   
2. To determine insulin sensitivity in vivo in these mice and in vitro in 3T3L1 
adipocytes. 
3. To determine the adipokine expression profile in WAT of Cbl -/- and Cbl +/+ 
animals and in 3T3L1 c-Cbl knockdown and control adipocytes. 
4. To investigate how a high fat diet affects WAT in Cbl -/- and Cbl +/+ mice. 









































2 Materials and methods 
2.1 Animals 
2.1.1 Generation of c-Cbl deficient mice: Cbl -/- mice were obtained from the 
laboratory of Dr. Richard Hodes at the National Institute of Health (USA). Originally, 
the Cbl -/- mice were generated by Naramura [182] on a C57BL/6 background, using 
a gene-targeting strategy as shown in Fig. 13A. One exon (second exon) of the c-Cbl 
gene was deleted from the targeting vector (embryonic stem (ES) cell clone), followed 
by electroporation of the targeting construct into E14.1 ES cells. ES cells were selected 
with G418 and ganciclovir. Double-resistant clones were detected for homologous 
recombination by southern hybridization. The targeted clones were transiently 
transfected with a Cre recombinase expression vector to remove the neomycin-
resistance gene and the second exon of the c-Cbl gene as indicated in Fig. 13A. Finally, 
resultant ES clones were injected into blastocysts to obtain chimaeric mice. In c-Cbl 
mutant mice, the absence of aberrant transcripts of the c-Cbl gene was confirmed by 
reverse transcription-PCR, and the Cbl protein was not detected by an antibody against 
the C terminus of the protein (Fig. 13B, C) [182].  
2.1.2 Animals and breeding: C57BL6/J wild type control mice (Cbl +/+) were 
purchased from the Jackson laboratories (Bar Harbour ME, USA). Cbl -/-  and Cbl +/+ 
mice were bred to obtain heterozygous animals (Cbl +/-) and expanded to obtain an 
experimental cohort of animals. After five generations of het x het breeding additional 
pairs of Cbl -/- x Cbl -/- and Cbl +/+ x Cbl +/+ were crossed within our colony to establish 
an adequate supply of animals for our experiments. In all experiments, Cbl +/+ 
littermate controls or age and gender matched control animals from our colony were 
used. Animals were housed in a pathogen-free animal facility, at the Biomedical 





















Fig. 13. Generation of Cbl-deficient mice by gene targeting [182]. (A) Partial 
restriction map of the c-cbl locus, the targeting construct, and the mutated c-cbl locus. The 
second exon in the figure, which was subsequently deleted by Cre/loxP-mediated DNA 
recombination, corresponds to nucleotides 681–837 of the published mouse c-cbl cDNA 
sequence (GenBank accession no. X57111). Black rectangles represent exons and 
triangles represent loxP sequence. Sa, SacI; S, SphI. (B) Reverse transcription–PCR 
analysis of c-cbl transcripts from wild-type (+/+), heterozygous (+/-), and homozygous 
(-/-) c-cbl mutant thymocytes. The sequences of the primers used in PCR correspond to 
nucleotides 640–663 (sense orientation) and to nucleotides 996-1019 (antisense 









2.2 Diet interventions 
The mice had free access to water and diet (standard chow: CRM (P), Rat and 
Mouse Breeder and Grower, standard AIN93G-based pelleted diet, product code 
801722, Special Diet Services, Witham, Essex, UK). This diet provided 3.59 kcal/g of 
energy with 9.08% calories as fat, 68.9% as carbohydrate (CHO) and 22.0% as protein, 
and contained fat, carbohydrate and protein at 3.4, 4.2 and 18.4% w/w respectively 
[183]. Two interventions were tested in this work. First, a group of animals were fed 
either the standard chow (as above) or a high fat diet (HFD) obtained from Special 
Diet Services (UK) containing 45, 20 and 35% of total energy intake deriving from 
fat, protein and carbohydrates respectively (diet code: 824053). The HFD experiment 
was started when animals were aged 4-5 weeks and maintained for 8 weeks. Body 
weight (BW) was recorded twice per week (Friday and Tuesday) from 4 to 12 weeks 
old. Second, the effects of fasting were studied. Animals at age 12-14 weeks of both 
genders were allowed free access to the standard chow diet every day; before the 
experimental day they were fasted overnight (5:00 PM to 8:00 AM) prior to sacrifice. 
Mice were sacrificed by decapitation for tissue dissections and blood was withdrawn 
via cardiac puncture. Blood was collected in tubes containing 8µl of EDTA (500 mM) 
and plasma was obtained by centrifugation at 2,000 x g for 10 min at 4 °C. Tissues 
were either snap frozen in liquid nitrogen then stored at -80 °C or cultured in Dulbeco 
Modified Eagle’s media (DMEM) high glucose until further biochemical and 
molecular analyses or fixed and preserved for histological analysis (as described in 
section 2.14). All animal procedures were performed according to the Animals 
(Scientific Procedures) Act, 1986, UK regulations for animal welfare [184] and with 




2.3 DNA preparation and genotype polymerase chain reaction (PCR) 
 Genomic DNA was prepared from an ear notch sample at 3 weeks of age using 
the proteinase K (Roche, REF 03115887001) protocol modified from [185]. Tissues 
were digested in lysis buffer pH 8.5 (100 mM Tris, 5 mM EDTA, 200 mM NaCl, 0.2 
% SDS and 100 μg/ml proteinase K) at 50°C, overnight. Then samples were vortexed 
for 10 seconds and centrifuged at 12,000 x g for 2 minutes. 5 µl were taken as an 
aliquot from the supernatant and diluted 1:20 in 95 µl RNase free water, followed by 
heat inactivation at 95 °C in a dry bath for 15 minutes, then placed on ice. 3-5 µl of 
that dilution was taken for a PCR reaction later. For the detection of the mice genotype 
a PCR was used to amplify specific sequences of the mouse genome. A specific DNA 
fragment was amplified from complex genomic samples by this technique. The 
genotype PCR was performed with Bio-Rad C1000™ PCR/Thermal cycler. PCR 
GoTaq polymerase from PROMEGA was performed (25µl per reaction). The reaction 
mixture contained: 4.0 µl DNA sample, 11.88 µl H2O, 5 µl of 5 x Flexi GoTaq buffer, 
1.5 µl of 25 mM MgCl2, 0.5 µl of 10 mM dNTP-mix, 1µl of 20 μM stock forward 
primers, 1µl reverse primers and 0.12 µl of 1U GoTaq HotStart-Pol. The reaction 
conditions were: 95°C for 2 min, 94°C for 45 sec, 55°C for 30 sec, 72°C for 1 min 
plus 35 cycles, then 72°C for 10 min and 4°C forever. Genotypes were determined by 
PCR of genomic DNA using the following primer sets: LOXP: 5’ TGG CTG GAC 
GTA AAC TCC TCT TCA GAC CTA ATA AC 3’; CBL-10: 5’ GAC GAT AGT 
CCC GTG GAA GAG CTT TCG ACA 3’; CBL-11: 5’ CCT AAG TGG TAG GAT 
TAT AAT TGC AAG CCA CCA C 3’ and CBL-13: 5’ TCC CCT CCC CTT CCC 
ATG TTT TTA ATA GAC TC 3’ which amplify the targeted and non-targeted genes, 
respectively. PCR products were visualised by agarose gel electrophoresis. A 2% 
agarose gel was made. DNA samples (8-10 μl per well) were loaded and separated by 
46 
 
electrophoresis at 100 v for 45 minutes. The expected product size are: ~200 bp for 
Cbl +/+ and ~250 bp for Cbl -/-. For reference a DNA ladder (100 bp, # 10488-058) was 
used. Results were visualized in a Syngene Gene Flash Bio Imaging Gel 
Documentation System. 
 
2.4 Food intake  
Mouse food intake was assessed for 8 weeks from week 4 to week 12 of age. At 
the beginning of the experiment, the cages and mice were weighed separately, and the 
mice were put in their cages for a designated experimental time. Body weight (n = 2-
4 mice per cage) and food intake was measured weekly (2-day per week, (every 
Tuesday and Friday) and averaged. Mice and cages with food were weighted 
separately. After that it was divided by the number of days and the number of animals 
per cage, to determine food intake per individual mouse. Results are presented as an 
average ± SEM. 
 
2.5 Blood glucose analysis 
Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were done to assess 
how quickly the glucose cleared from the blood; and to examine the body response to 
insulin independently of pancreatic function. The mice were fasted overnight (5:00 
PM to 8:00 AM). The next morning, BW was taken. The relative amount of glucose 
or insulin administration intraperitoneally (i.p.) was adjusted according to body weight 
of individual mice. Insulin solutionhuman recombinant (10mg/ml) from Sigma 
(#I9278), used in this study, is an intermediate-acting insulin with a slower onset of 
action and a longer duration of activity (up to 24 hours) than that of regular human 
insulin. Blood glucose concentrations were measured with a one-touch blood glucose 
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monitor (Freestyle Lite glucose monitor) at week 9-10 of age. GTT and ITT were 
analyzed as described [186, 187].  
2.5.1 GTT: GTT was performed on mice fasted overnight (16 hours). Glucose saline 
solution was prepared at a concentration of 30g/100 ml. Glucose at 2 g/kg of body 
weight was administered intraperitoneally (i.p.) and subsequently blood samples were 
obtained from the tail vein at the indicated times, 0 min before glucose administration, 
and 30 min, 60 min, 90 min, and 120 minutes post-injection. Glucose concentrations 
were measured using a glucometer (Freestyle freedom lite glucose monitor). 
2.5.2 ITT: ITT was performed on mice fasted overnight (16 hours). Animals were 
injected intraperitoneally with insulin (0.75 U/kg of body weight, 12 µl/20 ml of 
saline). Blood glucose concentrations were determined using the Freestyle Lite 
glucometer at 0 min, 30 min, 60 min and 90 minutes after injection.    
 
2.6 Indirect calorimetry 
In indirect calorimetry, energy expenditure (EE) is determined by measuring the 
the amount of oxygen consumed and carbon dioxide produced. The respiratory 
quotient (RQ), which provides information about metabolic substrate utilization (lipid 
or carbohydrate), is calculated by dividing the volume of CO2 produced by the volume 
of O2 consumed (RQ =VCO2 / VO2) [188-190]. In metabolism software (Metabolism 
(V3000), user manual) the following equation is used to calculate EE:           
                               EE = (3.815 + (1.232 x RQ)) x VO2 x 1.44 
Where 1.44 is the conversion factor to convert the cal/min unit into Kcal/day unit 
(1440 min/1000). 
Energy expenditure, respiratory quotient, activity, food intake and water 
consumptions were measured using a four-chamber indirect calorimetry system 
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(OxyletPro system from Panlab, Harvard apparatus, UK) and using metabolism 
software 3.0. The system detects air, and measures the gas concentration of the 
incoming and outgoing air for both O2 and CO2 in the sealed chambers [191]. 
Measurements were taken for one minute at every 15-minute intervals for 48hr. The 
experiment lasted for 48 hours, during which mice were free to consume food and 
water. Animals were housed individually in metabolic chambers and allowed to 
acclimatize for 4 hours (from 2:00 – 6:00 PM). Data from this first time of period were 
not used in the results analysis. The data including VO2, VCO2, energy expenditure, 
respiratory quotient (RQ) and spontaneous physical movement (activity) were 
simultaneously recorded for each mouse, over a 48-hr period under a constant 
environmental temperature (22°C), then used in analysis of the metabolic phenotype. 
EE, RQ and the activity of mice were then calculated from groups of 5-6 mice per 
experimental condition (per genotype and diet intervention). Graphs are made showing 
means and standard error.  
 
2.7 3T3L1 adipocytes culturing and differentiation 
Culture and differentiation of 3T3L1 adipocytes was carried out as described 
previously [192]. 3T3L1 cells were obtained from the American Type Tissue Culture 
repository. Cells were cultured in DMEM supplemented with 25 mM glucose, 10% 
calf serum at 37 °C with 8% CO2. Cells were differentiated into adipocytes with 
1µg/ml insulin, 1µM dexamethasone, and 0.5mM isobutyl-1-methylxanthine (IBMX), 
as described previously [192]. 3T3L1 cell lines stably expressing shRNAs specific for 
c-Cbl or empty PKLO puro vector or a non-targeting (NT)-shRNA were generated as 
previously described [193]. 3T3L1 fibroblasts were grown in DMEM media 
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supplemented with 10% calf serum, and 3 μg/ml of puromycin. Once confluent, cells 
were differentiated in regular differentiation media as above. 
 
2.8 3T3L1 adipocytes lysate 
Adipocyte cells were lysed in ice-cold lysis buffer (Hepes 50 mM pH=7.5, NaCl 
150 mM, EDTA 10 mM, sodium pyrophosphate 10 mM, 10% Glycerol, sodium 
vanadate 2 mM, NaF 100 mM, phenylmethylsulfonyl fluoride (PMSF) 2 mM, 1% 
Triton x-100, pepstatin A 2 µg/ml, leupeptin 2 µg/ml and aprotinin 2 µg/ml). Cells 
were serum starved for 24-hours and stimulated with insulin (at a final concentration 
of 100 nM) for 30 minutes as indicated in the figure legends. Cells were washed with 
ice cold PBS and then 0.2 – 0.5 ml of lysis buffer per well was added. Cells were then 
incubated on ice for 10-15 minutes in a rocking platform and centrifuged at 14,000 x 
g for 10 minutes at 4°C. The supernatant was taken for protein quantitation using the 
Bio-Rad (Bradford assay, 2.11). 
 
2.9 Culture of adipose tissue explants 
WAT adipose tissue explants were obtained according to the protocol of Fried 
[194]. Epididymal WAT was dissected from Cbl +/+ and Cbl -/- mice from both males 
and females aged 10-14 weeks and after dissection was directly placed into 5-10 ml of 
DMEM with high glucose. Tissue was transferred into a sterile Petri dish, minced into 
small pieces (1-2 mm diameter) under sterile conditions, and subsequently incubated 
for 2 hours in DMEM. After 2 hours of incubation, the media was changed to fresh 
DMEM and cultured further for up to 24 hours. Tissue was incubated in the presence 
of increasing concentrations of insulin (0 nM, 1 nM, 10 nM and 100 nM insulin) for 
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30 minutes (or as indicated in figure legends). Tissues were snap frozen in liquid 
nitrogen and stored at -80°C until analysis. 
 
2.10 Adipose tissue lysates 
Tissue samples were homogenised in a DOUNCE glass homogenizer, in ice-cold 
lysis buffer (NaCl 100 mM, EDTA 1 mM, 1% Triton x-100, NaF 50 mM, sodium 
pyrophosphate 2 mM, sodium vanadate 1 mM, PMSF 1 mM, pepstatin A 2 µg/ml, 
leupeptin 2 µg/ml and aprotinin 2 µg/ml). Samples were rotated at 4°C for 30 minutes, 
centrifuged at 14,000 x g for 15 min at 4°C and protein concentration of the 
supernatant was determined using the Bio-Rad (Bradford assay).  
 
2.11  Protein quantification (Bradford assay) 
 Total protein concentrations were measured in the tissue and cell lysates. The 
Bradford protein assay was performed (Bio-Rad # 500-0006). The reagent was diluted 
1:5 with distilled water. The standard curve was prepared using IgG (1mg/ml) from 
Bio-Rad. 200 µl/well of diluted reagent was placed into 96-well sterilin plates 
(Thermo-Fisher Scientific, Cat # 611F96). The IgG standard was added at 
concentration of 0, 1, 2, 4, 6, and 8 ug/µl into the assigned wells and 1-2 µl/well of the 
samples into the other wells. The absorbance reading for the samples and the standard 
was measured in duplicate at 595 nm using the plate reader (ELX 800). A standard 
curve was made and if the R square value for the standard was between 0.95-0.99 that 





2.12  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blot analysis 
2.12.1 Samples preparation for SDS-PAGE: Samples prepared for western blot 
contained equal amounts of protein (40-80 µg) and were placed into 1.5 ml Eppendorf 
tube. Then one third of the total volume of 3x concentrated Laemmli sample buffer 
(LSB), and distilled water were added to the samples, heated for 10 minutes at 95˚C 
to denature the proteins, and placed in ice for 1 minute; samples were then centrifuged 
for few seconds at 12,000xg. 
2.12.2 Gel preparation: SDS-PAGE gel was prepared to separate the proteins 
according to their molecular weight: 10 or 12% running gel pH 8.8 and stacking gel 
pH 6.8 was made. The glass electrophoresis plates were wiped and cleaned with 70% 
ethanol and the two plates then assembled together into a sitting rig. Sterile water was 
added to check for absence of leak and ensure that the plates were tightly sealed. Then 
resolving gel and stacking gels were made as described in the appendix. The chemical 
components of the stacking gel were mixed and then poured to the top of resolving gel 
between the plates and wells created by inserting a comb (1.5 mm thickness, 10 or 16 
wells). After 20-30 minutes, once the stacking gel was set the comb was removed 
vertically. Encased gels within the glass plates were transferred to a tank containing 
1L of 1X running buffer pH 8.6 (25 mM tris base, 192 mM glycine and 0.1% SDS). 
Samples were loaded using specific loading tips (Fisher, UK). Samples were resolved 
by electrophoresis, running voltage 110-120 v for 2-3 hours. To identify the molecular 
weight of the proteins in the samples a prestained protein ladder (10-250 kDa) ladder 




2.12.3 Protein transfer to the membrane (blotting) and its detection: After 
separation by SDS-PAGE, proteins were transferred into nitrocellulose membranes 
using the following steps. Transfer cassettes contained the following layers: the 
cathode ((-), black cassette face), sponge, Whatman filter paper, SDS-PAGE gel, 
nitrocellulose membrane, Whatman filter paper, sponge, and the anode ((+), white 
cassette face). All equipment was pre-soaked in transfer buffer and it was ensured that 
no bubbles were trapped between the gel and membrane. The transfer cassette was 
then placed in a transfer tank filled with transfer buffer pH 8.3 (25 mM tris base, 192 
mM glycine, 0.1% SDS and 20% methanol) for 1:30 hour at a constant 0.36 amps. 
Following the transfer, nitrocellulose membranes were stained with Ponceau stain to 
visualise protein transfer and distained in distilled water and TBST. Nitrocellulose 
membranes were treated with 5% skimmed dried milk in TBST (TBS/Tween (0.1%) 
for 1 hour at room temperature to block non-specific binding protein sites. The 
membrane was then washed three times in TBST for 10 minutes each and incubated 
at 4°C overnight with the primary antibody diluted in 3% BSA/PBS with 0.02% 
sodium azide. After washing three times in TBST for 10 minutes each, the membrane 
was incubated in secondary antibody conjugated with fluorescent dye, in 5% skimmed 
dried milk in TBST for 1 hour at room temperature. Nitrocellulose membranes were 
again washed three times in TBST for 10 minutes each. Proteins were then visualised 
by the Odyssey LICOR system scanner. The abundance of protein was determined by 
image analysis using an Image J software (NIH). 






2.13 Triglyceride (TG) quantification 
Triglyceride was determined with an enzymatic assay kit (free glycerol reagent, # 
F6428) and lipase (L1754, Sigma). The procedure involved enzymatic hydrolysis by 
lipase of triglyceride to glycerol and free fatty acids. Glycerol was further converted 
to glycerolphosphate by glycerol kinase and to dihydroxyacetone phosphate and 
hydrogen peroxide by glycerolphosphate oxidase. Subsequently, hydrogen peroxide 
(H2O2) together with 4-aminoantipyrine (4-AAP) and sodium N-ethyl-N-(3-
sulfopropyl) m-anisidine (ESPA) were added to produce a coloured quinoneimine dye 
which was spectrophotometrically detectable with maximum absorbance at 540 nm 
[195, 196]. Tissue homogenates were obtained as detailed in section 2.10. Lysates 
were incubated at 70°C for 5 minutes, cooled and 10 µl aliquots incubated with 5 µl 
of lipase (2 mg/1 ml in PBS) overnight at 37°C. Subsequently, triglyceride 
concentrations were determined by quantifying spectrophotometrically (540 nm) the 
released glycerol using a commercial kit, SIGMA-Free Glycerol Reagent F6428. The 
abundance of TGs was normalized to the protein content of the tissue homogenate 
(section 2.11) which was determined using the Bio-Rad protein assay kit. 
 
2.14  Immunohistochemistry of adipose tissue 
Adipose tissue (WAT and BAT) dissected from Cbl -/- and Cbl +/+ mice (male and 
female) was fixed in 4% PFA (4 gm paraformaldehyde /100 ml PBS) overnight at 4°C, 
then placed in PBS until processing. Samples were dehydrated through a series of 
ascending graded ethanol solutions (50, 70, 80, 95, 100%) for 10 minutes in each 
concentration. Following that, tissues were placed into a mixture of 50% isopropanol 
and 50% paraffin, which was pre-warmed in an incubator for 1 hour at 55-60 ̊C. 
Samples were then changed into paraffin for further 1 hour in the same conditions. The 
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paraffin was replaced with fresh paraffin and tissue was incubated overnight in the 
incubator. The next day, samples were embedded in a fresh paraffin peel-away and 
left to harden overnight before sectioning. 
2.14.1 Haematoxylin and eosin staining: Tissue was sectioned in a microtome (5-7 
µm thick sections), dewaxed in Histoclear (5 minutes, twice), rehydrated through a 
series of descending ethanol concentrations (100, 95, 80, 70, 50%) for 2 minutes in 
each, stained with Mayer’s haematoxylin (2 gm haematoxylin, 100 ml ethanol (100%), 
100 ml glycerol, 100 ml distilled water, 10 ml glacial acetic acid and 30 gm of 
potassium aluminium sulphate) for 8 minutes, rinsed in water and acidified water for 
10 seconds in each. Sections were counterstained with eosin for 2-3 minutes, washed 
in tap water dehydrated in ascending graded ethanol concentrations (50, 70, 80, 95, 
100%) for 1 minutes in each, cleared in Histoclear and mounted using dibutylphthalate 
polystyrene xylene (DPX) mounting medium. Sections were visualized in a Leica 
inverted microscope (Leica microsystems, equipment No.11227510) at 40x 
magnification and images taken with a colour camera (Leica DFC. 450C, Germany, 
541007) using a software program (LAS v4.2). Image analysis of histological tissue 
preparations (cell size and diameter) were carried out using Adiposoft-ImageJ 
software (is an automated open source software for the analysis of adipose tissue 
cellularity in histological sections)[197]. 
2.14.2 Immunohistochemistry for UCP-1: Immunolocalization was performed using 
ImmPRESS REAGENT Anti-Goat IgG reagent according to the manufacturer’s 
guidelines. The ImmPRESS™ staining system is based on a novel method of 
polymerizing enzymes and attaching these micropolymers to antibodies. It is 
characterized by very high sensitivity, increased signal intensity and considerably less 
background staining in immunohistochemical applications. Immunostains for UCP-1 
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(antibody: C-17, sc-6528 from Santa Cruz) were done simultaneously on serial 
sections on separate slides. In brief, 7 μm thick sections were deparaffinized in 
Histoclear and rehydrated in progressively reducing concentrations of ethanol (100, 
95, 75, 50, 25%) for 5 minutes in each. Antigen retrieval was performed heating the 
samples in Tris-EDTA buffer (pH 9.0) in a microwave oven in 2 cycles for 20 minutes 
in total in boiling buffer, followed by cooling at room temperature for 30 minutes. 
Primary antibody diluted in normal horse blocking serum (ImmPRESS REAGENT, # 
MP-7405) was applied to the sections which were then incubated overnight at 4°C. 
Endogenous peroxidase activity was blocked with 1% (v/v) H2O2 in PBS. Slides were 
placed in a humidified chamber during the incubation periods to prevent drying out. 
The slides were washed twice in PBS (5 min/wash), and the excess buffer was wiped 
away. Sections were encircled with wax using a PAP pen to minimize the volume of 
antibody solution needed for the immunohistochemical reaction. After washing in 
PBS, sections were blocked for 1 hour with provided ready-to-use (2.5% v/v) normal 
horse blocking serum to reduce the nonspecific signal. Sections were then incubated 
with monoclonal antibodies against UCP-1 (1:200), in blocking solution (normal horse 
serum) overnight at 4°C. To ascertain the specificity of the staining, negative control 
slides were included for each of the antibodies tested (is incubated without primary 
antibody, only with blocking serum). In these slides the primary antibody solution was 
substituted with blocking buffer. After washing in PBS 2 times for 5 minutes each, 
sections were incubated with the ImmPRESS™ reagent for 30 minutes at room 
temperature. After PBS washes (2 times/5min) peroxidase activity was developed with 
diaminobenzidine (DAB) as substrate. Sections were counterstained with Mayer’s 
haematoxylin for 1-2 minutes, dehydrated in ascending graded ethanol concentrations 
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(50, 75, 95, 100%) for 1 minute, cleared in Histoclear for 5 minutes, then mounted 
with coverslips using DPX mounting medium. 
 
2.15 ELISA determination of adipokine content, concentration 
Quantification of adipokine concentrations was determined by ELISA using 
commercially available kits (RBP4, adiponectin, leptin, R&D, Minnesota, USA; TNF-
α, IL-6, BD biosciences). Sandwich ELISA (enzyme-linked immunosorbent assay) is 
a technique designed to quantify proteins using specific antibodies. Sandwich ELISA 
measures the antigen between the two layers antibodies (capture and detection 
antibody). The capture antibody (primary antibody) was a monoclonal or polyclonal 
antibody specific for the protein (antigen) of interest and was diluted according to the 
manufacturers recommendations with 1x PBS and coated on a Falcon microplate 
(Ref.353279, Bioscience), then incubated overnight at 4°C. The plate was washed 3 
times with PBS/Tween (0.05%) and blocked with 3% BSA (Bovine serum albumin) 
in PBS for 2 hours at room temperature followed by washing 3 times with PBS/Tween 
(0.05%). Each assay used a standard made by recombinant adipokine supplied by the 
manufacturer. Both standard and samples were added and incubated overnight at 4°C. 
Standards and samples bind to this antibody, whereas unbound antigens are washed 
away. Next, an enzyme-labelled detection antibody (secondary antibody) specific for 
the antigen, was added for 1 hour at room temperature. The plate was washed 3-4 times 
with BPS/Tween (0.05%) and Streptavidin-HRP 1:5000 dilution was added for 1 hour, 
followed by washing 3 times with BPS/Tween (0.05%). Using a substrate, TMB 
(Tetramethylbenzidine), which is converted by the enzyme, a colour signal is 
generated; the protein amount is detectable as intensity of the colour. The reaction was 
stopped by adding 1N of H2SO4 and the plate reader (ELX 800) was set to detection 
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at 450 nm for measurement of samples and standard intensity. Finally, the results were 
normalized to total protein content determined by Bradford method. 
 
2.16 Total RNA 
Total RNA was isolated from WAT and liver, frozen WAT and liver (50- 100 mg) 
were placed into a 2 ml Eppendorf tube and 600 µl of TRI reagent (T9424, Sigma-
Aldrich UK) was added. The Trizol-tissue mixture was homogenized with a Polytron 
homogenizer (PT 1600E), the RNA from cell culture samples was extracted by 
scraping the cells in 600 µl of Tri reagent and centrifuged for 15 min at 14,000 x g at 
4°C. The clear supernatant was transferred to a fresh 1.5 ml Eppendorf tube and 200 
µl of chloroform (C2432, Sigma) was added per ml of Tri-reagent used, for 5 min.  
The solution was vortexed and centrifuged for 15 min at 14,000 x g at 4°C for phase 
separation. The aqueous layer was taken out in a fresh tube and supplemented with 
300 µl of 2-propanol (I9516, Sigma). After mixing, the solution was allowed to stand 
for 5-10 min at room temperature, followed by centrifugation at 14,000 x g for 30 min 
at 4°C. The RNA precipitate formed a pellet on the side and bottom of the tube. The 
supernatant was discarded, and the pellet washed twice with 500 μl of 75% ethanol 
solution, vortexed and centrifuged for 15 min at 14,000 x g at 4°C. The supernatant 
was then removed, and the pellet air dried for 5-10 minutes and then re-suspended in 
20-25 µ RNAse free water. Finally, the purity and concentration of isolated RNA were 
further measured on a NanoDrop™ Lite spectrophotometer (Thermo Scientific, 
840281500). The ratio of absorbances between 1.7-2.0 at both 260/280 and 260/230 




2.17 Analysis of mRNA expression by real-time quantitative PCR 
cDNA synthesis and quantitative PCR 
Total RNA was reverse transcribed to complementary DNA (cDNA) with an 
iScript cDNA synthesis kit (Bio-Rad, #170-8891). cDNA synthesis from 1.0 - 1.5 μg 
of total RNA was performed using the high-capacity cDNA reverse transcription Kit. 
The reaction mixture contained: 4 µl of 5x iScript reaction mix, 1 µl of iScript reverse 
transcriptase, x µl of nuclease-free water and x µl of RNA template to give a total 
volume of 20 µl. The tubes were briefly vortexed before being placed into a Bio-Rad 
C1000™ PCR/Thermal cycler. The reaction conditions were:5 min at 25 °C; 30 min 
at 42 °C; 5 min at 85 °C and  at 4 °C.  cDNA was then stored at -20°C until qRT-
PCR analysis. The cDNA was diluted 1:16 in RNase-free water prior to qRT-PCR in 
1.5 ml Eppendorf. Validated Taqman probes for RBP4 and 18S (assay IDs: 
Mn00803264-31 and Hs 99999901 respectively) were obtained from Life 
Technologies. The RT-PCR reaction conditions were started with preincubation at 
95°C for 3 min, denaturation step of 10 sec, at 95 °C followed by annealing 20 sec, at 
60 °C and 20 sec, at 72 °C for a total of 40 cycles.  
Estrogen  receptor isoforms α and β were amplified using Kapa Sybr green, Fast 
mix from Roche and the following primers: ERα: F: 5’TGATTGGTCTCGTCTG 
GCG3’; R: 5’CATGCCCTCTACACATTTACC3’; ERβ: F: 5'CTGGCTAACCTC 
CTGATGCT3’; R: 5'CCACATTTTTGCACTTCATGTTG3’ The primers produce 
amplicons of 100 bp and 91bp respectively. The conditions of the reaction were: 
denaturation 95ºC 30 seconds, annealing 60ºC 20 seconds, extension 72ºC 30 seconds, 
for 40 cycles. A melting curve was run at the end of each run. Relative quantification 
was carried out using the ΔΔCt method using 18S gene expression (primer sequences: 
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forward: 5’TCAAGAACGAAAGTCGGAGG3’ and reverse: 5’GGACATCTAAGG 
GCATCACA3’: for normalization, as we have previously reported [198]. 
The relative abundance of transcripts was quantified out using the ΔΔCT method. 
Data were obtained as CT values (CT=cycle number at which logarithmic PCR plots 
cross a calculated threshold line) and used to determine ΔCT values. ΔCT values of 
the target gene were normalized to ΔCT of 18S (reference gene) and ΔΔCT analysis 
was performed as described [199]. The calculation for quantitation first determined 
the difference (ΔCT) between the CT values of the target and the reference gene:  
ΔCT = CT (target gene) - CT (reference gene)    
The comparative (ΔΔCT) calculation was then used to determine the difference 
between each sample's ΔCT and the reference’s ΔCT. 
Comparative expression level = ΔCT (CT of the target gene) – (CT of the 
reference gene or housekeeping gene)  
Finally, these values were transformed to absolute values using the formula: Absolute 










































Cbl is an adaptor protein with an intrinsic E3 ubiquitin-protein ligase involved in 
protein ubiquitination and cell signalling previously found to play an important role in 
regulating translocation of the glucose transporter GLUT4 in 3T3L1 adipocytes [22-
24, 166, 168, 169]. 
Later, an unexpected role for c-Cbl in energy homeostasis was described [170, 
200]. c-Cbl knockout mice on a 129/SvJ x C57BL/6 background exhibited decreased 
adiposity despite hyperphagia and improved whole body insulin action resulting from 
increased muscle glucose uptake [22]. Cbl -/- mice also exhibited a profound increase 
in energy expenditure paralleled with increased mitochondrial density and respiratory 
capacity [22]. When fed a high-fat diet, Cbl -/- mice were reported to be protected from 
diet-induced weight gain and insulin resistance [18]. It is noteworthy that in another 
study, the same authors generated transgenic Cbl mice overexpressing a Cbl protein 
with mutated RING finger domain  (Cbl A/-) that also resulted in increased energy 
expenditure and protected mice from high-fat diet-induced obesity and insulin 
resistance [201]. These mice also displayed increased muscle AMPK activity [18, 22], 
elevated glucose uptake  [202] and increased fatty acid oxidation [203], indicating that 
Cbl E3 ubiquitin activity may be important for regulating AMPK fatty oxidation in 
muscle via AMPK .[201].  
However, the contribution of Cbl signalling in regulating glucose and lipid 
metabolism in WAT and adipokine production has not been studied in Cbl -/- mice 
before. The aim of this chapter was to determine the contribution of Cbl signalling to 
insulin sensitivity in mice generated on a C57BL6 background and to analyse the role 




3.1 Genotyping of Cbl -/- mice 
In order to expand the colony of mice and obtain animals for experimental use, we 
needed to confirm the genotypes of Cbl -/- mice. This was done by detecting the wild 
type (Cbl +/+) and the Cbl -/- alleles, in two PCR reactions (as described in Chapter 2). 
A representative PCR result confirming the genetic identity of the mice is shown in 
Fig. 14 A. To further confirm the genotypes of the founder mice, a tissue lysate was 
obtained from WAT separated by SDS-PAGE and immunoblotted with specific 
antibodies for c-Cbl and tubulin (used as a loading control). The absence of c-Cbl 













Fig. 14. Genotyping PCR for Cbl -/- and Cbl +/+ mice. A) The genotype of Cbl mice 
indicated by PCR (“-/-” Cbl -/-, “+/+” Cbl +/+, “-/+”, Cbl -/+ mice). B) Left, western blot 
analysis obtained from Cbl +/+ and Cbl -/- mice using Cbl and tubulin antibodies; right, 








3.2 Body weight and food intake in Cbl -/- mice 
To assess whether c-Cbl depletion in mice results in changes in adiposity, body 
weight (BW) was recorded twice per week for 8 weeks following weaning at week 
four (Fig. 15A). In parallel, food intake was evaluated (see 2.4). Male Cbl -/- exhibited 
no significant difference in BW compared with male Cbl +/+ mice, while female Cbl -/- 
mice had slightly lower BW compared to wild type females at week four. Even so, 
there was little difference in body weight gain. Male Cbl -/- mice showed a higher food 
intake compared to wild type male mice (Fig. 15B), whereas in female Cbl -/- mice 



















Fig. 15. Growth curves and food intake for Cbl -/- and Cbl +/+ mice. A) Growth curves 
for Cbl -/- and Cbl +/+ mice. BW was slightly decreased in female Cbl -/- mice. Data shows 
mean ± SEM of  weekly weight (Cbl +/+: male
 
n=18, female n=12; Cbl -/-: male n=14, 
female n=17. B) Food intake for Cbl -/- and Cbl +/+ mice (n=7-10 males per groups and 
n=3 females per groups). Food intake was significantly increased in male but not in female 
Cbl -/- mice. Graphs show mean ± SEM. Statistical analysis: multiple and unpaired t-test 














3.3 White adipose tissue morphology and triglyceride content 
Previous findings by Molero et al.[18, 22] had reported that the Cbl -/- mice on the 
129/SvJ x C57BL/6 background had reduced adipose tissue mass. To determine 
whether Cbl -/- mice on a C57BL6 background displayed differences in AT 
morphology, we examined histological sections of perigonadal WAT by haematoxylin 
and eosin staining (Fig. 16A, B, C, D). We found no differences in adipocyte 
morphology or cell size in the samples obtained from young (12 weeks) or old (30 
weeks old) mice (Fig. 16A, B, C, D). These data were then extended to include 
biochemical determination of triglyceride content. We found that the triglyceride 
content of adipose tissue from male Cbl -/- mice was significantly lower compared to 
Cbl +/+ littermates with no significant changes detected in female mice (Fig. 16E).  
 
3.4 Brown adipose tissue morphology, UCP-1 expression and 
triglyceride content 
We next examined BAT morphology in histological sections of interscapular 
adipose depots. We found that adipose cell size of BAT from male Cbl -/- mice was not 
different from that of male Cbl +/+ in young (12 weeks) or old (30 weeks old) mice 
(Fig. 17A, B). No differences were observed in triglyceride content of BAT between 
Cbl -/- and Cbl +/+ mice (Fig. 17C). We did not detect any difference in UCP1 








Fig. 16. White adipose tissue (WAT) morphology and triglyceride content. No 
changes in adiposity in Cbl -/- mice. A) Haematoxylin-eosin staining of  epididymal WAT 
of  Cbl -/- and Cbl +/+
 
male mice at 12 weeks of  age (top panel) and at 30 weeks (bottom 
panel). Representative images are shown of  histochemical pictures obtained at 40X 
magnification. B) Quantification: Adiposoft-ImageJ was used to quantify cell diameter of  
n=100 cells and cell area n=50 cells per sample. Top graphs correspond to 12 weeks old 
mice Cbl +/+
 
n=9 and Cbl -/-n=12, and bottom to 30 weeks old mice, n= 3 Cbl +/+ and 4 
Cbl -/-. There was a slight decrease in adipocytes area and cell diameter in old age Cbl -/- 
compared to Cbl +/+. C) WAT obtained from female mice (12 weeks old) Cbl +/+
 
n=9 and 
Cbl -/-n=12. D) Shows quantification of  female adipocyte cell area and cell diameter of  
n=100 cells and cell area n=50 cells per sample. E) Triglyceride content in WAT obtained 
from age matched (12-14 weeks old) Cbl +/+
 
and Cbl -/- mice, n=10-15 mice per genotype 
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Fig. 17. Brown adipose tissue morphology and triglyceride content. A) 
Haematoxylin-eosin staining of  brown adipose tissue of  male Cbl +/+
 
and Cbl -/-mice. 
Representative images are shown of  pictures obtained at 40X magnification. Top panels 
are mice at 12 weeks old and the bottom panels are at 30 weeks of  age. B) Quantification: 
Adiposoft-ImageJ was used to quantify cell diameter n=100 cells and cell area n=50 cells 
per genotype. Top graphs correspond to data obtained from 12 weeks old male and the 
bottom graphs to 30 weeks old male mice. 12 weeks Cbl +/+
 
and Cbl -/-mice n= 4-6 mice 
per group and 30 weeks old male mice n=4. C) Triglyceride content of  BAT in age 
matched (12-14 weeks) Cbl +/+
 
and Cbl -/- mice.  Data represent the means ± SEM of  12 




Fig. 18. UCP-1 expression in BAT obtained from Cbl -/- and Cbl +/+ mice. A) Left 
panel shows a representative western blot of UCP-1 in BAT lysates obtained from Cbl -/- 
and Cbl +/+ mice. B) Right panel shows the blot quantification. Graphs are mean ± SEM 












Fig. 19. Immunohistochemical analysis of  UCP-1 in Cbl -/- and Cbl +/+ mice. 
Immunohistochemistry was performed on BAT sections using UCP-1 antibody, the goat 
anti-mouse antibody (1:200) and ImmPRESS REAGENT Anti-Goat Ig, peroxidase Kit 
(Vector Laboratories) as specified in the methods section. Top panels show a negative 
control without the primary antibody. Bottom panels show reactivity in the presence of  




3.5 The effects of c-Cbl depletion on insulin sensitivity  
Cbl -/- mice from the 129/SvJ x C57BL/6 background had been shown to be more 
insulin sensitive than wild type mice [22]. We examined insulin sensitivity in vivo in 
Cbl -/- mice on a C57BL6 background (Fig. 20). We performed in vivo whole-body 
glucose tolerance tests and insulin tolerance tests in overnight fasted mice at week 9-
10 of age.  
Similarly to what was observed in the previous study [22], we found that Cbl -/- 
mice showed a tendency towards an increase in glucose tolerance although it did not 
reach statistical significance for either gender (Fig. 20A). However, ITT in male Cbl -
/- mice showed improved insulin sensitivity (Fig. 20B) but this was not observed in 
female mice. 
We next examined whether insulin signalling cascades were altered in vitro in 
white adipose tissue obtained from perigonadal depots (Fig. 21). To do this, we 
cultured adipose tissue explants that were then either untreated or stimulated with 
insulin for 30 minutes at final concentrations of 0 nM, 1 nM, 10 nM and 100 nM. 
Whole tissue lysates were obtained, and we determined the activation or 
phosphorylation of AKT (PI3 Kinase) and MAPK signalling pathways by western blot 
analysis. We observed that insulin effectively activated PI3-kinase to a similar extent 
in both genotypes as determined by the level of phosphorylation of AKT at Ser473 
seen in both male and female Cbl -/- and Cbl +/+ (Fig. 21A, B, D, E). However, while 
the maximal activation of ERK proteins was achieved to a similar extent with 
submaximal insulin concentrations in the two genotypes, both male and female Cbl -/- 
mice showed a greater ERK phosphorylation in the basal (untreated) state with 
approximately 40% more phosphorylation of p44/p42 compared to Cbl +/+ mice (Fig. 
21A, C, D, F) even though the abundance of total ERK protein in the lysates was 
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similar. One possible contributor to the increased insulin sensitivity is enhanced 
abundance of insulin signalling molecules in Cbl -/-. Thus, we next examined the 
expression of insulin receptors substrate-1 (IRS-1) and insulin-responsive glucose 
transporter GLUT4 in WAT (Fig. 22A). We found that the protein content of IRS-1 
and GLUT4 in WAT of Cbl -/- compared to Cbl +/+ control were not different (Fig. 















Fig. 20. Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) in Cbl -/-  
and Cbl +/+mice. A) Top left panels represent GTT curves and the right panels are area 
under the curve (AUC) in female and male mice. GTT was slightly decreased in female 
and male Cbl -/- mice compared to the control. B) Bottom left panels show ITT curves 
and right panels represent AUC in female and male mice. ITT was significantly decreased 
in male Cbl -/- mice and slightly so in female Cbl -/- mice compared to their respective wild 
types. Tests were carried out at weeks 9-10 of  age. Mice were injected with glucose 2 g/Kg 
of  body weight or insulin 0.75 U/Kg of  body weight and at the times indicated, blood 
tail samples were obtained, and glucose measured using a glucose meter. Graphs show 
mean ± SEM of  values, male Cbl +/+
 
n = 5, Cbl -/-  n = 4; female Cbl +/+
 
n = 3, Cbl -/-  n 





Fig. 21. Insulin activation of PI3K and MAPK pathways in white adipose tissue of 
Cbl -/- and Cbl +/+mice. Increased activation of ERK in adipose tissue of Cbl -/- mice. 
White adipose tissue explants of  Cbl -/- and Cbl +/+male A) and female mice D) were 
obtained and either untreated or treated with insulin at the indicated concentrations (0-
100nM), separated onto SDS-PAGE and immunoblotted with antibodies as indicated. 
Panels B) C) E) and F) show the quantification of  AKT and ERK phosphorylation 
relative to the total AKT or ERK protein respectively from 5 experiments. Graph shows 
mean ± SEM of  phosphorylation over basal as % of  Ser473 (AKT) or T202/204 and 













Fig. 22. Expression of insulin signalling proteins and glucose transporter GLUT4 
in WAT obtained from Cbl -/- and Cbl +/+ mice. A) Expression of IRS-1 and GLUT4. 
B) and C) Quantification of expression relative to actin. Graphs show mean ± SEM of 
n=4 Cbl -/- and n=8 Cbl +/+ mice. Statistical analysis: unpaired t-test. 
 
 
3.6 Effects of c-Cbl knockdown in 3T3L1 adipocytes 
The data described above suggested that c-Cbl depletion enhances MAPK 
signalling in Cbl -/- mice. To confirm that c-Cbl gene depletion was directly responsible 
for the changes in signalling in adipose tissue in the Cbl -/- mice and was not due to 
alterations in other organs, we reasoned that depletion of c-Cbl expression in the 
adipocyte 3T3L1 mouse cell line would replicate the findings seen in vivo. To this end, 
undifferentiated 3T3L1 cells were either untreated or infected with lentiviral particles 
expressing validated shRNAs for the c-Cbl gene (Cbl KD) or infected with lentiviral 
particles expressing a non-targeting shRNA (NT-shRNA) or infected with lentiviral 
particles containing an empty vector (EV) as an additional control. Stable cell lines 
were selected in the presence of puromycin as our group has previously reported [192] 
and following amplification the selected cells were differentiated to obtain fully 
differentiated adipocytes [193]. No changes were observed in the differentiation of 
3T3L1 cells between Cbl KD and control (NT-shRNA and WT) cells as observed by 




Expression of c-Cbl in differentiated 3T3L1 cells was significantly reduced in Cbl 
KD cells compared to cells expressing NT-shRNA or EV (Fig. 24A). Insulin treatment 
resulted in the activation of the PI3-kinase cascade and phosphorylation of AKT in 
Ser473 to a similar extend in Cbl knockdown cells compared to control cells (Fig. 24A, 
B). Interestingly as found in vivo, we detected enhanced phosphorylation of ERK in c-
Cbl knockdown cells compared to control cells (Fig. 24A, B). No change was observed 
in the expression of insulin receptor IR between NT-shRNA and Cbl KD 3T3L1 cells 
(Fig. 24C, D). 
 
Fig. 23. Differentiation of 3T3L1 adipocytes. Control cells or c-Cbl deficient 3T3L1 
adipocytes were differentiated as described in Chapter 2.  Images were taken for each 















Fig. 24. The PI3K and the MAPK pathways and AMPK in 3T3L1 cells. A) Increased 
activation of  ERK in c-Cbl Knockdown 3T3L1 adipocytes. Fully differentiated 3T3L1 
adipocyte cells expressing control plasmids (empty vector EV or NT-shRNA) or 
expressing shRNAs for c-Cbl (Cbl KD) were left untreated (0) or stimulated with insulin 
(100 nM) for 20 minutes (20). Cellular lysates were obtained, loaded onto SDS-PAGE and 
immunoblotted with the indicated antibodies. Representative blot of  5 experiments. B) 
Shows the quantification as mean ± SEM of  intensities in arbitrary units of  AKT (Ser473) 
and ERK (T202/204 and Thr185/Tyr187) respectively, obtained in 5 independent 
experiments. Statistical analysis: ANOVA-one way, Tukey's multiple comparisons test, 
***indicates p<0.001; **** p < 0.0001. C) IR expression in 3T3L1 cells. Left panel 
western blot of 3T3L1 cells shows NT-shRAN and Cbl KD. D) Right panel shows 
quantification of the blot. Graphs are mean ± SEM of n=3 experiments. Statistical 









3.7 AMPK signalling in WAT of Cbl -/- mice and in 3T3L1 Cbl KD 
cells 
Previously, Molero et al.[22] found an increase in AMPK activity in skeletal 
muscle from c-Cbl -/- mice. Activation of AMPK in adipocytes inhibits lipolysis [204, 
205]. We sought to determine whether AMPK was more readily activated in 
adipocytes depleted of c-Cbl. We examined the relative abundance of AMPK 
phosphorylation at the Thr172 site in WAT lysates obtained from Cbl -/- or Cbl +/+ 
mice. As a positive control for our western, we included cellular lysates obtained from 
adipose cells that had been treated with 5-Aminoimidazole-4-carboxamide 
ribonucleotide (AICAR) a pharmacological activator of AMPK. We observed no 
significant differences in AMPK phosphorylation in Cbl -/- and Cbl +/+ mice (Fig. 25A, 
B). On the other hand, we found that AMPK phosphorylation was significantly 
reduced in Cbl KD 3T3L1 cells compared to NT-shRNA, with no significant change 










Fig. 25. AMPK phosphorylation in WAT obtained from Cbl -/- and Cbl +/+ mice.  
A) Left panel western blot analysis of phospho-AMPK*thr) in WAT from Cbl -/- and Cbl 
+/+mice and AICAR treated 3T3L1 cells. B) Right panel shows the quantification. Graphs 




Fig. 26. AMPK phosphorylation in 3T3L1 cells. A) Left panel, western blot for 
phospho-AMPK of cellular lysates obtained from 3T3L1 cells expressing either vector 
(EV), NT-shRNAs or shRNAs for Cbl KD. B) Right panel, quantification of data 
obtained in 4 independent experiments (n=10 biological replicates). Graphs are mean ± 











In the present study, we tested the hypothesis that c-Cbl deficiency impacts on 
adiposity and insulin responsiveness in C57BL6 mice. It had been  previously shown 
by Molero et al. [18, 22] that Cbl -/- mice on a different background showed reduced 
adiposity, triglyceride levels and increased food intake than control mice. We 
determined that Cbl -/- mice on a C57BL6 background did not display any significant 
growth differences compared with Cbl +/+ mice. However, food intake was 
significantly higher in male Cbl -/- compared to wild type mice, while triglyceride 
content in WAT was significantly lower in male Cbl -/- compared to Cbl +/+ mice, which 
might be attributable to increase energy expenditure in Cbl -/- mice. These findings 
were consistent with the studies of Molero et al. [18, 22]. 
It was reported that c-Cbl depletion increases muscle metabolism, enhanced energy 
expenditure and reduced adiposity [22]. The Cbl -/- mice used in our studies did not 
show any adipose tissue morphology abnormalities or differences in adipocyte cell 
size, which contradicts the findings of Molero et al. [22] who reported  lower adipocyte 
diameter in Cbl -/- compared to wild type. These findings suggest small differences in 
the phenotype that may be attributable to distinct genomic backgrounds. 
Earlier studies [23, 169] have reported that c-Cbl protein is a vital component of 
the insulin signalling pathway in 3T3-L1 adipocytes that regulates insulin-stimulated 
glucose transport. Another study [206] reported that suppression of c-Cbl in 3T3-L1 
adipocytes by RNA interference-mediated (RNAi-mediated) had no effect on insulin-
stimulated glucose transport and suggested that Cbl proteins are not a required for 
insulin signalling and GLUT4 regulation in either cultured 3T3-L1 or primary 
adipocytes from Cbl -/- mice [206]. Molero et al. [18, 22] found that glucose tolerance 
and insulin sensitivity were improved in Cbl -/- mice on a Jvs129 x C57BL6 
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background, and they observed a considerable increase in muscle insulin-stimulated 
glucose uptake both in vivo and ex vivo. In the current study, we observed the male 
Cbl -/- mice replicated the insulin sensitivity phenotype described in the previous 
studies [18, 22], but females were not significantly different to wild type.  
The improvement in insulin sensitivity in Cbl -/- mice, suggested there might be an 
increase in insulin signalling pathway in Cbl -/- mice. To confirm these findings, we 
examined insulin signalling in WAT through PI3K and MAPK pathways. We found 
increased basal activation of ERK1/2 in the adipose tissue of Cbl -/- mice. Consistent 
with our finding, Zhang et al. [207] also showed that the absence of c-Cbl increased 
ERK phosphorylation in c-Cbl -/- bone marrow-derived mast cells (BMMC) compared 
to the control cells [207]. 
To confirm the finding that c-Cbl gene depletion was directly responsible for the 
increased basal ERK phosphorylation levels and not due to some systemic effect, we 
established 3T3L1 adipocyte cells depleted of c-Cbl (Cbl KD 3T3L1). We observed a 
significant increase in ERK phosphorylation levels in Cbl KD cells compared to 
control cells, similar to our finding in Cbl -/- mice. Together the data indicate that 
deletion of c-Cbl gene is responsible for increasing MAPK activity. It has been 
published that activation of MAPK had profound effects on the differentiation program 
of 3T3-L1 preadipocytes [208, 209] by increasing the phosphorylation of PPARγ 
[209]. Thus, inhibition of ERK1/2 resulted in reduced adipocyte differentiation [210, 
211]. However, we did not observed differences in the differentiation of 3T3L1 
adipocytes between Cbl KD and control cells (NT-shRNA and WT). 
However, it remains possible that the effects of increased ERK1/2 activation might 
be dependent on Cbl action as an E3-Ubiquitin ligase for example acting on ERK1/2 
regulatory proteins, targeting an upstream ERK kinase or through an inhibitory effect 
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of an ERK phosphatase. In addition, the regulation of MAP kinase activity by Cbl may 
be mediated by intermediary molecules, because no direct interaction between Cbl and 
MAP kinases has been established [182]. Cbl might control MAP kinase activation by 
inhibiting tyrosine kinases (such as ZAP-70) that have been shown to be linked with 
MAP kinase activation in T cells. Alternatively, SOS, a Ras GDP release factor, and 
Cbl bind to the same SH3 domain of Grb2, an adaptor protein known to interact with 
phosphorylated receptors and to link RTKs with activation of the Ras pathway. 
Therefore, Cbl may compete with SOS for binding sites on Grb2 and consequently 
reduce the number of Grb2 molecules available for SOS-mediated activation of the 
Ras-MAP kinase pathway [182, 212]. Further research is necessary to identify the 
molecular mechanisms for increased basal ERK1/2 phosphorylation in c-Cbl depleted 
adipose cells. 
 Indeed, c-Cbl proteins have dual functionalities. They act as adaptor proteins for 
tyrosine kinase receptors, including the insulin receptor, and recruit signalling proteins 
in the caveolae of adipose cells [213]. In addition, c-Cbl proteins can function as an 
E3-ubiquitin ligase enzyme, thus facilitating the degradation of proteins including 
TKR. Molero et al. [22] had found increased insulin receptor expression in the skeletal 
muscle of Cbl -/- mice. However, we did not detect any changes in the expression levels 
of the glucose transporter GLUT4 or IRS-1. Furthermore, we found signalling through 
PI3-kinase in response to insulin was unremarkable in Cbl -/- compared to the wild type 
mice indicating equal insulin receptor substrate-1 and PI3-kinase activation. This was 
consistent with Molero et al. [18] who found no significant difference in the 
phosphorylation of AKT in Cbl -/- compared with Cbl +/+ mice, in the absence of insulin 
stimulation, when they examined skeletal muscle.  
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We next examined the impact of c-Cbl deletion on AMPK activation in WAT of 
Cbl -/- mice and 3T3L1 Cbl KD cells. Molero et al. [22] found an increase in AMPK 
activity in skeletal muscle from Cbl -/- mice. We found no significant differences in 
phospho-AMPK in WAT of Cbl -/- compared to Cbl +/+ mice. Whereas in 3T3L1 cells, 
AMPK phosphorylation was significantly lower in Cbl KD 3T3L1 compared to NT-
shRNA 3T3L1 cells. Daval et al. [204] reported that activation of AMPK in muscle 
increases fatty acid oxidation. However, in adipocytes several studies report an anti-
lipolytic effect of AMPK [205, 214, 215], whereas others suggest AMPK stimulates 
lipolysis [216, 217]. AMPK is activated in adipose tissue in conditions of increased 
lipolysis such as exercise and fasting [204, 205, 218, 219]. This activation inhibits 
fatty acid and triglyceride synthesis and could limit lipolysis [204]. This is might be 
the reason for detecting no changes in AMPK activation in Cbl -/- mice because we 
examined these mice in a fed state. 
In this chapter, we have shown that c-Cbl depletion in adipocytes is associated with 
increased basal activation of extracellular regulated kinases (ERK1/2) in both Cbl -/- 
mice and c-Cbl knocked-down 3T3L1 adipose cells. Further research is necessary to 
identify the underlying molecular mechanisms. Moreover, it seems possible that one 
































Adipose tissue was for many years considered to be energy storage organ, but it is 
now recognized as an active endocrine organ that secretes a variety of bioactive 
molecules, known as adipocytokines or adipokines [89, 220], that contribute to the 
regulation of metabolism [13]. Adipokines act as circulating hormones to 
communicate with other organs including: the brain, liver, muscle and the immune 
system, but they also act in an autocrine manner to have effects on adipose tissue itself 
[16]. Adipokines are recognized to have multiple functions including: regulating food 
intake, insulin sensitivity and modulating inflammatory processes [62]. For example: 
leptin functions as a satiety factor and suppresses food intake in the hypothalamus [13, 
16]; in the periphery, leptin increases fatty acid oxidation notably in skeletal muscle 
and improves insulin sensitivity through the activation of AMPK [13, 89, 101]. 
Moreover adiponectin has direct actions on liver, skeletal muscle and the vasculature, 
where it improves hepatic insulin sensitivity, increases muscle fatty acid oxidation and 
decreases vascular inflammation [221]. Additionally, RBP4 is involved primarily in 
the transport of retinol in the circulation [121], however, it has also been shown that 
increased RBP4 levels impair insulin signalling in muscle and liver [13, 121], and its 
expression is inversely correlated with that of GLUT4 in adipocytes [127].   
Macrophages residing within AT secrete other proinflammatory cytokines 
including TNF-α and IL-6 that also contribute to the development of insulin resistance 
[8, 89, 95].  
I reported in the previous chapter, that c-Cbl depletion in mice and in 3T3L1 cells 
increases basal ERK (p44/p42) activation in white adipocytes. In this chapter I tested 
the hypothesis that c-Cbl, through this signalling pathway, may contribute to the 
production and secretion of adipokines/cytokines such as adiponectin, leptin, RBP4, 
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IL-6 and TNF-α that might influence insulin sensitivity and/or insulin resistance 
related to obesity and T2D. 
To determine whether an altered expression of these adipokines could contribute 
to increased insulin sensitivity. I examined the expression in WAT of Cbl -/- and Cbl 
+/+ mice using a protein array and ELISA. I determined the circulating levels of several 
adipokines in both fed and fasting conditions. The findings were confirmed in the 
3T3L1 c-Cbl knockdown adipocyte cell line and in control 3T3L1 cells.  
 
4.1 The effects of c-Cbl deletion on adipokine expression in WAT of 
Cbl -/- mice 
To determine the molecular mechanisms of increased insulin sensitivity in Cbl -/- 
mice and to determine whether altered expression of white adipose adipokines could 
contribute to this effect, we sought to investigate the adipokine profile in visceral 
WAT, plasma and liver of Cbl -/- mice and their littermate controls using an adipokine 
protein array. The latter allows for the rapid detection of 24 different adipokines. Cells 
and tissues (WAT and liver) were homogenized as specified in chapter 2 sections 2.8 
and 2.10 respectively. 
We found that the expression of several adipokines was altered in Cbl -/- mice (Fig. 
27). These include: resistin, intercellular adhesion molecule 1 (ICAM-1) and insulin-
like growth factor-binding protein 3 (IGFBP-3). The expression of these proteins was 
increased significantly in Cbl -/- mice compared to wild type controls (Fig. 27). There 
was also an increase in RBP4, adiponectin, IL-6, IGFBP-2, lipocalin-2, leukemia 
inhibitory factor (LIF) and vascular endothelial growth factor (VEGF) abundance in 
Cbl -/- mice compared to Cbl +/+ mice. In contrast, we found a decrease in the expression 
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of leptin, insulin-like growth factor-binding protein 5 (IGFBP-5) and FGF acidic in 
Cbl -/- mice compared to the control Cbl +/+ mice. 
 
 
Fig. 27. Protein array for adipokine in WAT of  Cbl -/- and Cbl +/+.  Altered 
expression of  adipokines in WAT of  male Cbl -/- mice. Tissue lysates were obtained 
from perigonadal WAT and adipokines quantified by protein array kit. Graphs show 
mean ± SD. Cbl +/+
 
and Cbl -/- mice, n=2 male mice per genotype. 
 
These findings were suggestive of a change in adipokines that regulate insulin 
sensitivity, however this method while informative is not quantitatively accurate. To 
confirm the results and quantify the relevant adipokines, we validated our data by 
ELISA or qPCR. All ELISAs were carried out according to the general protocol 
specified in section 2.15 and section 2.17 for qPCR.  
Validation of the results by ELISA revealed a marked gender dimorphism in the 
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28A, B), the abundance of adiponectin was significantly reduced, whereas that of 
leptin was markedly increased. No significant difference was found in IL-6 in WAT 
of female Cbl -/- compared to female Cbl +/+ mice, whereas IL-6 in male Cbl -/- was 
significantly reduced compared to male Cbl +/+ mice (Fig. 28C). TNFα abundance in 
WAT was slightly decreased in male Cbl -/-, but this was not statistically significant 
(Fig. 28D), with no change observed in female mice.  
The abundance of RBP4 in WAT of female Cbl -/- mice was significantly increased 
(Fig. 29A). Despite the changes in RBP4 protein levels, no significant changes in the 
mRNA abundance of RBP4 were detected in WAT (Fig. 29B) of either gender. In 
contrast, the mRNA abundance of RBP4 in the liver of Cbl -/- mice was markedly 
elevated compared to that in Cbl +/+ mice for both gender (Fig. 29D). However, this 
did not translate into differences in protein abundance (Fig. 29C).  
In the steady state, plasma levels of adiponectin, leptin or RBP4 were 
unremarkable in Cbl -/- compared to Cbl +/+ mice (Fig. 30A, B, C).  
We then sought to confirm these data using the 3T3L1 adipocyte cell line depleted 
of c-Cbl and compared to control cells. Differentiated adipocytes were homogenized 
and the adipokine content analysed by ELISA. We found that RBP4 abundance was 
significantly increased in the Cbl KD cells compared to the control cells, leptin 
abundance was slightly elevated in the c-Cbl depleted cells although this did not reach 
statistical significance. No changes were observed in adiponectin compared to control 







Fig. 28. Adipokine expression in WAT. Altered expression of  adipokines in WAT of  
female Cbl -/- mice. Tissue lysates were obtained from perigonadal WAT and adipokines 
quantified by ELISA as specified in the methods section. Adipokine levels were 
normalized to the total protein content in the lysate. A) adiponectin, B) leptin and C) IL-
6 and D) TNF-α in WAT (Cbl -/- n= 3 males, 3 females and Cbl +/+ n= 7male, 3 females). 
Graphs show mean ± SEM, statistical analysis: unpaired t-test, * indicates p<0.05; ** 










































Fig. 29. RBP4 expression in WAT and liver. Increased protein abundance of  RBP4 in 
WAT of  female Cbl -/- mice and increased mRBP4 abundance in the liver of  Cbl -/- mice 
for both gender. Tissue lysates were obtained from perigonadal WAT or liver and 
adipokines quantified by ELISA as specified in the methods section. A) RBP4 in WAT 
(Cbl -/- n= 6 males, 12 females, Cbl +/+ n= 15 males, 13 females). B) Gene expression of  
RBP4 abundance relative to 18S determined by qPCR in WAT (Cbl -/- male= 3, female=3 
and Cbl +/+ male = 3, female= 3). C) RBP4 in liver (Cbl +/+: male
 
n=4, female n=5; Cbl -
/-: male n=4, female n=8). D) RBP4 mRNA abundance relative to 18S in liver determined 
by qPCR (Cbl -/- male= 3, female=3 and Cbl +/+male = 3, female= 3). Graphs show mean 








































Fig. 30. Adipokine concentrations in plasma. No differences in the plasma abundance 
of  adiponectin, leptin and RBP4. Mice were fasted for 6 hours and euthanized. Plasma 
was obtained and adipokines were quantitated by ELISA as described in the methods 
section 2.2 and 2.15 respectively. Graphs show mean ± SEM, statistical analysis: unpaired 





Fig. 31. Adipokine expression in 3T3L1 cells. RBP4, Adiponectin and leptin 
expression were determined in total cellular lysates by ELISA from control (expressing 
empty vector (EV) or Non-targeting shRNAs) or Cbl KD cells (expressing shRNAs for 
c-Cbl). Graphs are mean± SEM of  N=5 sample replicates. Statistical analysis: unpaired 
























4.2 Effects of fasting on adipokine expression in the Cbl -/- mice 
Calorie restriction and starvation increase the production of anti-inflammatory 
adipokines such as adiponectin. In contrast, there is a decline in the production of pro-
inflammatory adipokines such as leptin and RBP4 and cytokines like IL-6 and TNFα, 
which informs the host of energy deficits and contributes to the suppression of immune 
function [222]. To determine whether c-Cbl signalling is involved in the fed/fast 
transition expression of these adipokines, we determined the adipokine profile in WAT 
of fed and fasted mice. For this experiment mice were deprived of food for 16 h and 
then euthanized, blood collected for plasma, and tissues were harvested and frozen for 
analysis. Tissue lysates were obtained and the adipokine content quantified by ELISA 
as above. No significant change was observed in the adiponectin and leptin content in 
WAT of Cbl -/- mice of both genders compared to their respective fed controls (Fig. 
32A, B). However, RBP4 abundance was significantly increased in WAT of fasted 
Cbl -/- female mice (Fig. 32C), while no difference was found in male Cbl -/- mice. On 
the other hand, a significant reduction in plasma adiponectin concentrations in Cbl -/- 
for both genders was observed (Fig. 33A), and plasma leptin was significantly 
decreased in male Cbl -/- (Fig. 33B). No changes were observed in the plasma 
concentrations of RBP4 in Cbl -/- for either gender (Fig. 33C). In addition, no 
differences were observed in the RBP4 abundance in the liver following an overnight 

















Fig. 32. Adipokine expression in WAT of  fast Cbl -/- and Cbl +/+ mice. RBP4 protein 
expression was increased in female Cbl -/- mice. Tissue lysates were obtained from 
perigonadal WAT and adipokines quantified by ELISA as specified in the methods 
section. Adipokine abundance was normalized to total protein content in the cellular 
lysate. A) adiponectin and B) leptin in white adipose tissue (Cbl -/-male n=4 and female 
n=3; Cbl +/+ male n=8 and female n=10). C) RBP4 abundance in WAT (Cbl -/- male n=5 
and female n=4; Cbl +/+ male n=6 and female n=12). Graphs show mean ± SEM, 






















Fig. 33. Adipokine expression in plasma of  fast Cbl -/- and Cbl +/+ mice. Plasma 
adiponectin was significantly reduced in both male and female Cbl -/- with a significant 
decrease in the plasma leptin of  male Cbl -/- was detect. A) adiponectin, B) leptin and C) 
RBP4 concentration in plasma (Cbl -/- male n=3 and female n=3; Cbl +/+ male n=3 and 





Fig. 34. Expression of  RBP4 in the liver of  fast Cbl -/- and Cbl +/+. No change in 
liver RBP4 protein expression in fasted Cbl -/-mice (Cbl -/- male n=5 and female n=4; Cbl 
+/+ male n=9 and female n=3). Data represent means ± SEM. Statistical analysis: unpaired 
t-test.  
 
4.3 Chemical inhibition of ERK 1/2 decreases RBP4 expression in 
WAT explants of Cbl -/- mice and in Cbl KD 3T3L1 adipocytes  
Since in the previous chapter we had observed that c-Cbl deficiency increases basal 
activation of extracellular regulated kinases p42/p44 in white adipose tissue we 
decided to investigate whether this signalling pathway is responsible for the elevated 
expression of RPB4 in Cbl -/- mice. To test this hypothesis, we examined the impact of 
chemical inhibition of MEK1/2 kinases which regulate ERK in the adipose tissue 
explants of Cbl -/- mice and in 3T3L1 Cbl KD cells (Fig. 35).  
Visceral adipose tissue explants were obtained and cultured in vitro in DMEM in 
the absence or presence of two chemical inhibitors of MEK1/2 (10 µM of PD98059 
and 20 µM of U0126) for 3 and 24 h. Subsequently, adipose tissue was collected, and 
lysates or total RNA were extracted. The efficacy of ERK pathway inhibition was 
determined by western blot analysis of the lysate proteins (Fig. 35A). Both inhibitors 
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significantly reduced ERK signalling as evidenced by reduced p42/p44 
phosphorylation after 24 h treatment although U0126 seemed to cause a greater 
inhibition (Fig. 35A). Concomitantly with this reduction in ERK activation the content 
of RBP4 in the tissue lysates was determined by ELISA and found to be decreased 
following the treatment with inhibitors (Fig. 35B). Again, U0126 was found to have 
greater effects compared to PD98059. At the mRNA level, treatment with both 
MEK1/2 inhibitors reduced RBP4 mRNA relative abundance after 3 h (Fig. 35C). 
RBP4 mRNA abundance recovered completely after 24 h following the treatment with 
PD98059 whereas a 50% decrease was still noted for U0126 at this time point (Fig. 
35C).  
We then sought to confirm these findings in the 3T3L1 Cbl KD cell system. Cbl 
KD 3T3L1 adipocytes were left untreated or treated with MEK1/2 inhibitors (10 µM 
of PD98059 and 20 µM of U0126) for 15 h. Cell lysates were obtained and analysed 
by western blot (Fig. 35D). Both inhibitors significantly reduced ERK phosphorylation 
in Cbl KD cells. Relative mRNA abundance of RBP4 analysed by real time PCR and 
found to be significantly decreased after treatment with inhibitors (Fig. 35E). The 







































Fig. 35. Inhibition of  ERK in adipose tissue explants of  Cbl -/- mice and in c-Cbl 
depleted 3T3L1 adipocytes reduces RBP4 expression. A) Treatment of  adipose 
tissue explants of  Cbl -/- mice with ERK inhibitors (PD98059 and U0126) reduces 
phosphorylation of  ERK. Adipose explants were treated with 10 µM of PD98059 and 20 
µM of U0126 for 3 and 24 h. Tissue lysates were analysed by western blot with phospho-
specific ERK antibodies as described in the methods section 2.12. Left shows a 
representative blot, right graph shows quantification of  data obtained from n=3 animals 









tissue explants treated with ERK inhibitors for 24h. Data are the mean ± SEM for n=3 
mice for each inhibitor. C) mRNA quantification of  RBP4 in white adipose tissue 
explants left untreated or treated with ERK inhibitors for 3h (left panel) or 24h (right 
panel). Graphs are mean ± SEM of  relative quantification to 18S as a housekeeping gene, 
data obtained from n=2 mice for each inhibitor, each sample quantified in triplicate. D) 
Cbl KD 3T3L1 adipocytes were either untreated or treated with ERK inhibitors for 15h. 
Cell lysates were obtained and analysed by western blot. Graph is quantitation of an 
experiment done in triplicate. Representative of two independent experiments each done 
in triplicate biological samples. E) mRNA abundance of RBP4 quantitated in c-Cbl 
depleted 3T3L1 adipocytes either untreated or incubated with inhibitors for 15h. Graph 
shows mean ± SEM. Representative experiment of n=2, with 3 biological replicates. 

























4.4  Estrogen receptor regulates RBP4 expression in adipocytes 
The previous findings indicate that RBP4 increased significantly in WAT of 
female Cbl -/- mice.  Since WAT expresses abundant estrogen receptors (ER) we 
hypothesized that the increase in RBP4 in female Cbl -/- mice might be related to the 
effects of estrogen  on adipocytes. 
To test the hypothesis, we first examined whether 17β-estradiol regulates RBP4 
expression in adipocytes. Differentiated 3T3L1 adipocytes were treated with 17β- 
estradiol (E2) at a range of concentrations (0, 10 -7, 10 -8 and 10 -9 M) for 15 h 
(Fig.36A). Total RNA was subsequently harvested and mRNA abundance of RBP4 
determined by qPCR. We found that 17β-estradiol increased RBP4 mRNA in 
adipocytes (Fig. 36A) compared with untreated cells. 
We next examined whether c-Cbl depletion in adipocytes would alter the 
expression or activation of estrogen receptors (ER). We determined the expression of 
ERα and ERβ by qPCR in control cells and in cells stably expressing shRNAs for c-
Cbl KD. We observed that Cbl KD 3T3L1 did not change the expression of estrogen   
receptors as no change was found in mRNA of ER-α and mRNA of ER-β between 












Fig. 36. Expression of RBP4 mRNA and ER-α and ER-β mRNA in 3T3L cells. 
A) 17β-estradiol increases RBP4 mRNA in 3T3l1 cells. Differentiated adipocytes were 
treated with E2 at a range of concentrations from 0 to 10-9M as indicated for 15 h. A) 
Total RNA was isolated and RBP4 mRNA abundance relative to 18S was determined 
by qPCR as described in the methods. Graphs shows mean ± SEM of n=3 cell dishes. 
One-Way ANOVA *** indicates<0.001. B) Expression of ER receptors in Cbl KD 
3T3L1 cells. Total RNA was isolated from control or c-Cbl depleted 3T3L1 
adipocytes and the mRNA abundance of ERα and ERβ relative to 18S were 
determined by qPCR as described in the methods. Graphs shows mean ± SEM of 
















4.5 c-Cbl depletion increases the phosphorylation of estrogen   
receptor alpha (ER-α) at S118 
Previous published studies [223-225] have established that ER-α can be activated 
by MAPK (P44/42) at phosphorylation site S118. Having determined that c-Cbl 
deficient adipocytes have increased ERK signalling, we next tested whether c-Cbl 
depletion would increase the phosphorylation of ER-α at this site. We evaluated the 
phosphorylation of ERα receptor at S118 by western blot analysis in WAT explants 
obtained from Cbl -/- and Cbl +/+ mice and in 3T3L1 Cbl KD and control cells. Tissue 
and cellular lysates were separated by SDS-PAGE and immunoblotted with a phospho-
ERα S118 antibody and a total ERα antibody as loading control. 
We observed a two-fold increase in ER phosphorylation in female Cbl -/- compared 
to female Cbl +/+ control, although this did not reach statistical significance (Fig. 37A); 









Fig. 37. ERα S118 phosphorylation in WAT of Cbl -/- and Cbl +/+ and in Cbl KD 
3T3L1 adipocytes. Increased ERα S118 phosphorylation in Cbl depleted adipocytes. A) 
White adipose tissue extracts obtained from Cbl -/- or Cbl +/+ mice (n=3 male and n=3 
female for each genotype) were immunoblotted with anti-phospho ERα (S118) antibody 
or ER antibody as loading control. The blot was quantified with Image J. Graph shows 
mean ± SEM of intensities in arbitrary units. B) Whole cell lysates obtained from either 
control 3T3L1 adipocytes or c-Cbl depleted cells were immunoblotted with anti-phospho 
ERα (S118) antibody or total ER as loading control. Graph shows the quantification in 
Image J of n=3-5 replicate samples per group and represents the mean ± SEM of 
phospho ER/ER ratio in arbitrary units as % of control cells which do not express 















WAT secretes numerous adipokines that affect body physiology. In the current 
study, I tested the hypothesis that Cbl -/- mice have altered expression of adipokines 
that might regulate whole body insulin sensitivity and/or glucose and lipid 
homeostasis. We determined the adipokine expression profile in WAT and plasma and 
confirmed the results in 3T3L1 cells.  
Regarding gender, we observed a clear dimorphism in WAT content of some 
adipokines notably that of RBP4 in WAT of female Cbl -/- mice. 3T3L1 Cbl KD cells 
also displayed elevated RBP4 compared with control cells, but there was. no 
significant difference in RBP4 content in the liver or in the circulating plasma levels 
in Cbl -/- mice in the steady state. It is known that some adipokines are expressed 
differently depending on gender. For example, higher circulating concentrations of 
leptin and adiponectin are found in women [226, 227]. A possible direct role of 
gonadotropins on the expression of RBP4 has also been suggested, as circulating RBP4 
concentrations are higher in postmenopausal compared with premenopausal women 
and in women older than 50 years when compared with those younger than 50 years 
[129, 228, 229].  
In the present study, we examined other adipokines involved in insulin sensitivity 
including adiponectin and leptin, and cytokines IL-6 and TNF-α in Cbl -/-, Cbl +/+ and 
3T3L1 cells. We found that adiponectin was significantly reduced in WAT of female 
Cbl -/- mice, whereas, no significant changes were observed in adiponectin levels in 
Cbl KD 3T3L1 cells. On the other hand, we found that leptin was markedly increased 
in WAT in female Cbl -/- mice accompanied with an increase in Cbl KD 3T3L1 cells. 
In contrast to our results, Shimizu et al. [230] observed higher circulating levels of 
leptin in women compared to men and Kennedy et al. [231] suggested that the gender 
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differences in leptin synthesis are due to the stimulating roles of estrogen s and/or an 
inhibition effect of circulating androgens, while other authors have been unable to find 
a correlation with gender or sex hormones [232]. In the case of IL-6 there was a 
reduction in WAT of male Cbl -/- mice, with no change observed in females. Also, no 
significant change was observed in TNF-α in Cbl -/- mice for either male or female. 
In terms of fasting, it is known that adipose tissue shrinks during calorie restriction, 
anti-inflammatory adipokines rise and proinflammatory adipokines decline, resulting 
in increased insulin sensitivity, suppressed inflammation, protection against 
cardiovascular disease, improved glucose homeostasis in T2D and increased the life 
span in mice [222]. We determined the effects of overnight fasting on adipokine 
expression in Cbl -/- and control Cbl +/+ mice. We found that RBP4 was increased in 
WAT of female Cbl -/- mice after an overnight fast, with no difference observed in the 
circulating RBP4 or in RBP4 content in the liver. The liver is the major site for the 
synthesis and secretion of RBP4 [233-235] which presumably explains why 
circulating RBP4 was not significantly altered in Cbl -/- mice. Consistent with our 
findings, Kos et al. [138] reported that circulating RBP4 concentrations were 
independent of AT-RBP4 secretion and that there was higher RBP4 mRNA expression 
in adipose tissue in women when compared with men. Several studies however, have 
found no correlation between adipose RBP4 mRNA expression and serum protein 
concentrations [137, 138, 236, 237]. Ost et al. [238] showed that RBP4 is likely 
released from the adipocytes and acts locally to inhibit phosphorylation of IRS1 at 
serine 307, thereby disrupting insulin-mediated nutrient sensing. However, Norseen et 
al. [133] found that RBP4 indirectly impairs insulin action in adipocytes by inducing 
proinflammatory cytokine production from macrophages. This effect of RBP4 is 
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mediated, in part, through the activation of JNK and toll-like receptor 4 (TLR4) 
pathways and is independent of retinol binding to RBP4 [133].  
On the other hand, circulating adiponectin in Cbl -/- mice fasted overnight was 
significantly decreased in both genders. Our data contrasts with the findings of Molero 
et al. [22] who reported no change in fasting adiponectin levels in the circulation in 
Cbl -/- mice. Also, in human, Merl et al. [239] reported that serum adiponectin 
concentrations remain stable after 3 days of fasting and decline slightly during a 
prolonged fast. On the other hand, we observed that circulating leptin in male Cbl -/- 
was significantly decreased following an overnight fast, which is consistent with 
previous studies [240, 241], and it is consistent with the findings of Molero et al. [22] 
in Cbl -/- mice. A Previous study by Ahren et al. [242] reported that plasma leptin was 
reduced during fasting related to the changes of plasma insulin in mice [242]. 
We reported in previous chapters that ERK activation was increased in basal 
conditions in WAT of Cbl -/- mice and in Cbl KD 3T3L1 cells. In the current chapter, 
we found that there is an increase in RBP4 protein expression in WAT of female Cbl 
-/- and Cbl KD cells. We hypothesized that increased signalling through ERK may 
regulate RBP4 levels in WAT in Cbl -/- mice. To test this hypothesis and to investigate 
whether ERK signalling has a role in regulating RBP4 expression in Cbl -/- mice, we 
used chemical inhibitors (PD98059 and U0126) of MEK1/2 kinases to block ERK 
phosphorylation in adipose tissue explants of Cbl -/- and 3T3L1 Cbl KD cells. We 
found that inhibition of ERK1/2 phosphorylation in Cbl-depleted 3T3L1 adipocytes or 
in adipose tissue explants of Cbl -/- mice reduced RBP4 at the protein and mRNA 
levels. These findings suggest that c-Cbl may regulate RBP4 expression through 
ERK1/2 activation. Li et al. [243] reported that RBP4 enhanced ERK phosphorylation 
in vascular smooth muscle cells (RASMCs). A recent study observed that activation 
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of MAPK signaling increased in response to RBP4 treatment, and MAPK inhibitors 
significantly reduced RBP4-mediated expression of proinflammatory genes [244]. 
However, in contrast to our finding, Öst et al. [238] reported that RBP4 impaired 
insulin-stimulated ERK signaling in adipocytes [238]. 
Regarding the gender dimorphism, we observed elevated RBP4 only in female 
mice. Similar findings were found previously in humans [138]. It is known that both 
ER-α and ER-β estrogen receptors are expressed in WAT with ER-α being the most 
abundant. These receptors play an important role during adipose tissue differentiation, 
and act as ligand-dependent transcription factors to regulate the expression of specific 
genes [245-247]. The estrogen receptors are members of the nuclear hormone receptor 
superfamily of transcription factors that bind estrogen response elements (ERE) 
sequences as homo or heterodimers. ERs contain two transcription activation 
functions: AF1 located in the N-terminal A/B domain and the AF2 located in the C 
terminal domain. AF2 is activated through ligand (hormone) binding, whereas AF1 
can modulate gene transcription in the absence of ligand [248], but this is weak. 
Binding of estradiol to the ER-α facilitates ligand-dependent activation and 
transactivation of ERE in target genes, which activate or repress gene expression [249, 
250]. Estrogen actions are also mediated by ligand-independent ERα signalling that 
alter the phosphorylation of ERα [251, 252]. The human RBP4 promoter has ERE 
sequences in conserved regions, which suggests a role for ER in controlling 
expression. In support of this, we found that incubation of mouse adipose cells with 
17β-estradiol increased RBP4 mRNA. Our data are consistent with previous findings 
by Jung and coworkers [253] who found that in 3T3L1 adipocytes, ER-α but not ER-
β activation increased RBP4 mRNA abundance. Also, Tan et al. [254] showed in an 
earlier study that the RBP4 expression is influenced by effect of sex hormones and 
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suggested 17β-estradiol has a direct regulatory effect on RBP4 concentrations in 
women with polycystic ovary syndrome.  
We did not determine the oestrous cycle in our female mice or indeed measured 
the circulating estradiol levels to correlate them with RBP4 expression levels. Further 
work along these lines is required. However, there is already evidence from human 
studies for a correlation of RBP4 serum concentrations with those of estradiol and 
estradiol/testosterone [255], which supports the role of ER in the in vivo regulation of 
RBP4 expression. The effects of other female hormones released during the oestrous 
cycle on the expression of RBP4, however, have not been extensively studied. A recent 
study in heifers showed RBP4 at the mRNA and protein levels to be raised in 
endometrium during the dioestrus phase with elevated progesterone [256]. This may 
be related to the role of retinoic acid signalling in the expression of proteins important 
for embryo implantation [257]. Unfortunately, the authors did not measure RBP4 in 
WAT of these animals.  
AKT and ERK phosphorylation sites on ER-α map to S167 for AKT and S118 for 
ERK, both within the AF1 domain, and potentially leading to ligand-independent 
activation of ER-α [248, 252]. AF1 works to synergize with AF2 in the promotion of 
ligand-dependent transcription activation by the receptor [258]. Thus, we postulated 
that this mechanism may operate in the female Cbl -/- mice to enhance the expression 
of RBP4. We observed increased phosphorylation of ER-α at S118, in Cbl -/- and in 
Cbl KD 3T3L1 cells. Based on our findings, we suggest that along with the increased 
number of ER receptors and estrogen circulating concentrations present in females, c-
Cbl depletion may activate ER through ERK-mediated phosphorylation of ER-α at 
S118 which results in higher RBP4 expression.  
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All our data suggest that inhibition of c-Cbl in adipose tissue will increase RBP4 
expression locally. It was previously reported that Cbl signalling is impaired in animal 
models of insulin deficiency and in obesity [259]. This study reveals a potential new 
molecular mechanism that may contribute locally to the dysregulation of RBP4 that 
occurs in obesity and insulin resistance. 
In conclusion, in the current chapter a marked gender dimorphism was found in 
WAT content of some adipokines, leptin and RBP4 were significantly increased in 
WAT of female Cbl -/-, whereas adiponectin was reduced in female Cbl -/- mice. Fasting 
increased RBP4 protein expression in WAT of female Cbl -/- mice and decreased 
circulating adiponectin in both genders in Cbl -/- mice, while circulating leptin 
decreased only in male Cbl -/- mice compared to littermates control Cbl +/+. In Cbl KD 
3T3L1 adipocyte, RBP4 levels were increased compared to control cells. 17β-estradiol 
increases RBP4 mRNA in 3T3l1 cells, whereas c-Cbl depletion increases the 










































Obesity is considered a multi-factorial metabolic disturbance, prominent factors 
that determine the onset of obesity are the caloric content of the diet and the level of 
physical activity [260].  
Obesity affects the release of adipokines which are thought to cause insulin 
resistance and diabetes [261]. For example: in both humans and animals obesity leads 
to an increase in the circulating concentrations of leptin [262] and increased production 
of inflammatory cytokines such as TNF-α and IL-6, and the activation of the 
inflammatory signaling network [263, 264]. Kahn and colleagues reported that the 
development of obesity leads to increased expression of RBP4 by adipocytes, 
influencing metabolic disease development [127, 265]. Furthermore, both 
experimental and clinical studies have demonstrated a role for RBP4 in the 
development of insulin resistance [266, 267]. Thus, targeting the adipokines associated 
with visceral obesity may be a useful strategy for preventing obesity-induced 
metabolic disorders [261].  
In chapter 3 I established that Cbl -/- mice displayed increased insulin sensitivity 
compared to Cbl +/+ mice. I also showed in chapter 4 that several adipokines including 
adiponectin, leptin and RBP4 were differentially expressed in WAT of female Cbl -/- 
mice. In this chapter we hypothesized that a high fat diet differentially affects the 
release of these adipokines in Cbl -/- mice. We hypothesize that the release of insulin-
sensitizing adipokines (adiponectin, leptin) is greater in Cbl -/- mice whereas pro-
inflammatory cytokines (RBP4, TNF-α and IL6) levels are lower in Cbl -/- mice 
exposed to HFD. We further hypothesized that Cbl -/- mice maintain insulin sensitivity 




The specific aims for this chapter are: to determine insulin sensitivity in vivo, 
adiposity and adipokine profiles of WAT in Cbl -/- and wild type mice fed a high-fat 
diet (HFD) and compare them to mice fed regular chow (RC). 
 
5.1 Effects high fat diet on body weight, food intake and adiposity 
Dietary lifestyles that incorporate a high-fat diet are prone to cause obesity and 
T2D over time. Obesity is commonly seen with a variety of mice and rat strains, 
particularly in C57BL/6J (B6) mice when weaned onto these diets during juvenile 
stages, as it increases the risk for weight gain, hypertension and increases susceptibility 
to T2D symptoms, which include hyperglycaemia, as well as hyperinsulinemia [268, 
269]. To study the physiological adaptation of Cbl -/- mice to a HFD, we selected a diet 
containing 45 % of fat  [18, 270, 271]. We chose to feed the mice HFD for 8 weeks 
following the post-weaning period starting from week 4 [272].   
Body weight (BW) was recorded twice per week (as detailed in section 2.2). While 
the animals did put on weight, significant differences were observed between genotype 
groups (Fig. 38A). BW in both male and female Cbl -/- mice fed a HFD were 
significantly increased compared to HFD-fed control mice Cbl +/+.  
Regarding food intake, male Cbl -/- mice on a RC diet displayed a significant 
increase in food intake compared to their littermate controls (Cbl +/+) on the same diet 
(Fig. 38B). No significant difference was observed in food intake of either male or 
female Cbl -/- mice on a HFD compared to control Cbl +/+ mice fed the same diet. 
Adipocyte cell size and triglyceride content from perigonadal visceral fat were 
measured in animals fed a regular diet or HFD (Fig. 39). Adiposoft-ImageJ software 
was used for the analysis of WAT cell area and diameters as indicated in the methods 
section 2.14.1. Male Cbl -/- mice fed a HFD showed a significant increase in adipocyte 
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cell diameter compared to control mice fed a regular chow diet (Fig. 39B), while no 
significant differences were detected in adipocyte cell size of female Cbl -/- mice 
compared to control female Cbl +/+ for either regular chow or HFD (Fig. 39D). On the 
other hand, triglyceride content was not significantly different in male or female Cbl -





















Fig.  38. Growth curve and food intake in Cbl -/- and Cbl +/+ mice on HFD and RC 
diet. A) Growth curve of  Cbl -/- and Cbl +/+ mice on HFD and RC. Body weight in Cbl 
-/- on HFD was significantly increased in both genders. Data represent the mean ± SEM 
of  weekly weight. Cbl +/+
 
HFD, n=9 male and n=3 female, RC n=7 male and n=3 female; 
Cbl -/-
 
HFD, n=4 male and n=3 female, RC n=3 male and n=3 female. Two-way ANOVA, 
Tukey's multiple comparisons test, ** indicates p<0.01, **** p<0.0001. B) Food intake in 
Cbl +/+
 
and Cbl -/- mice. Daily food intake for both genotype which starting from week 4. 
RC and HFD (n=7-10 male per group and n=3 female per group). Food intake is 
significantly increased in RC male Cbl -/-. Two-way ANOVA, Sidak's multiple comparisons 











Fig. 39. Morphology of  WAT in Cbl -/- and Cbl +/+ mice on HFD and RC diet. No 
changes in adiposity of  HFD Cbl -/- mice. Haematoxylin-eosin staining of  perigonadal 
WAT obtained from male (A) and female (C) Cbl +/+ and Cbl -/- mice on RC and HFD. 
Representative images shown of  pictures obtained at 40X magnification (RC: male Cbl 
+/+ n=6, female Cbl +/+ n=3 and male Cbl -/- n=4, female Cbl -/- n=3; HFD: male Cbl +/+ 
n=7, female Cbl +/+ n=3 and male Cbl -/- n=4, female n=3) mice. RC Cbl -/- (top right 
panel) and RC Cbl 
+/+
 (top left panel), HFD Cbl -/- (bottom right panel) and HFD Cbl +/+ 
(bottom left panel). B) and D) Quantification: Adiposoft software was used to quantify 
cell diameter of  n=100 cells and cell area n=50 cells per genotype and gender. Graphs 
show mean± SEM. Statistical Analysis: ANOVA-one way, Tukey's multiple comparisons 




Fig. 40. Triglyceride content in adipose tissue obtained from Cbl -/- and Cbl +/+ 
mice. Triglyceride content in perigonadal WAT obtained from male (A) and female (B) 
age matched Cbl +/+ and Cbl -/- mice. (RC: male Cbl +/+ n=6, female Cbl +/+ n=3 and male 
Cbl -/- n=5, female Cbl -/- n=3, HFD: male Cbl +/+ n=7, female Cbl +/+ n=3 and male Cbl 
-/- n=5, female n=3) mice.  Graphs show mean± SEM. Statistical Analysis: ANOVA-one 




5.2 Insulin sensitivity studies in Cbl -/- mice fed a HFD 
Glucose tolerance tests revealed that the Cbl -/- mice had an enhanced glucose 
clearance and significant improvement in insulin sensitivity when fed a HFD 
compared to Cbl +/+ littermates (Fig. 41A, B). Insulin tolerance test were significantly 
lower in male Cbl -/- fed a HFD compared to control male Cbl +/+ mice on a HFD (Fig. 
41C, D), while no significant differences were observed in GTT or ITT in female Cbl 
-/- on a HFD compared to control female Cbl +/+ mice on the same diet (Fig. 41A, B, 
C, D). Collectively these data indicate that Cbl -/- mice are protected from developing 
HFD-induced insulin resistance, similar to what have been determined previously by 





















Fig. 41. Glucose and insulin tolerance tests in Cbl -/- and Cbl +/+ mice on HFD. A) 
Glucose tolerance test (GTT) and B) Area under the curve (AUC) for GTT in male and 
female Cbl -/- and Cbl +/+ mice. C) Insulin tolerance test (ITT) and D) AUC for ITT in 
male and female Cbl -/- and Cbl +/+ mice. Tests were carried out at week 10-11 of age. 
Mice were injected with glucose 2 g/Kg of body weight (GTT) or insulin 0.75 U/Kg of 
body weight (ITT) and at the times indicated, blood tail samples were obtained, and 
glucose measured using a glucose meter as indicated in the methods section. Graph shows 
mean ± SEM of values. Male mice n=4, female mice n=3 per genotype. Statistical analysis: 













5.3 Respiratory quotient, energy expenditure and activity in Cbl -/- 
mice fed a HFD 
We next examined substrate utilization and energy expenditure in mice after HFD 
feeding. Energy is generated by consuming substrates (carbohydrate, fat, and protein). 
Each substrate produces a different amount of energy (kcal) and a different cost in 
terms of CO2 to be produced. The ratio of CO2 produced to O2 consumed is referred to 
as the respiratory quotient (RQ = VCO2/VO2) [188]. RQ measures energy expenditure, 
at rest it gives us the value of the basal metabolic rate. It gives an indication of the 
primary metabolic substrate that is used, and normally is a number between 0.7 and 1 
[273]. The body mainly uses carbohydrates and lipids for oxidation to obtain ATP 
although amino acids can be used too [274]. In general, the reaction of oxidation for a 
metabolic substrate can be written as: 
CxHyOz + (x + y/4 – z/2) O2 → x CO2 + (y/2) H2O 
So, knowing the volume of oxygen consumed and CO2 produced an estimate can be 
made of the nutrient that has been used as a metabolic substrate. 
Full oxidation reaction for a carbohydrate:  
CnH2nOn + nO2 → nCO2 + nH2O 
gives us a RQ=1 
 So, if we consume carbohydrates RQ will be 1, whereas if we oxidize fatty acids, it 
will be approximately 0.7 [274]. 
In this study, following the diet intervention in which animals were fed a regular 
chow or high fat diet for 8 weeks, the mice were housed individually in a metabolic 
cage for 48 h to measure the respiratory quotient, energy expenditure and physical 
activity. This was accomplished using the OXYLET indirect calorimetry system, as 
described in the methods section 2.6.  
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We found that RQ significantly increased in male Cbl -/- mice on a RC diet during 
both dark and light phases compared to male control Cbl +/+ mice on the same diet 
(Fig. 42A), with no change observed in RC female Cbl -/- mice (Fig. 42C). The mean 
± SD of RQ in mice fed a RC was 1.067 ± 0.029 vs 1.038 ± 0.043 during the dark 
cycle and 0.985 ± 0.041 vs 0.947 ± 0.060 during the light cycle in male Cbl -/- and Cbl 
+/+ mice respectively (Fig. 42A). While in female mice RQ was 1.029 ± 0.041 and 
1.053 ± 0.052 during the dark cycle and 0.970 ± 0.044 and 0.960 ± 0.0515 in the light 
cycle in Cbl -/- and Cbl +/+ mice respectively (Fig. 42C). Since these numbers are close 
to 1.0 the data indicate that carbohydrates are used as the main fuel source.  
On the other hand, no change was found in the RQ in male Cbl -/- mice fed a HFD 
compared to control Cbl +/+ mice. The RQ was decreased significantly in female Cbl -
/- mice fed a HFD during dark and light cycle. The average RQ in mice fed a HFD was 
0.956 ± 0.016 and 0.948 ± 0.015 during the dark cycle and 0.922 ± 0.022 and 
0.911±0.018 during the light cycle in male Cbl -/- and Cbl +/+ respectively (Fig. 42B). 
However, in female mice the average RQ on HFD was 0.874 ± 0.043 and 0.906 ± 
0.021 in dark cycle and 0.852 ± 0.017 and 0.889 ± 0.021 in Cbl -/- and Cbl +/+ mice 
respectively (Fig. 42D). The RQ between 0.85-0.90 is an indication that both protein 
and carbohydrate have been used as a primary source of energy. These findings suggest 
that the substrate utilization of mixed protein and carbohydrate was used specially in 
the female Cbl -/- mice which exhibited significantly lower RQ than the male mice.  
Male Cbl -/- mice on RC diet exhibited a significant higher energy expenditure, 
during both dark and light cycle (Fig. 43A) whereas female Cbl -/- showed higher EE 
during the light cycle (Fig. 43C) only when compared to their control Cbl +/+ 
littermates. The average of EE in mice on RC diet was 136.66 ± 5.52 vs 128.19 ± 6.37 
during dark cycle and 120.35 ± 3.89 vs 113.33 ± 7.41 during light cycle in male Cbl -
121 
 
/- and Cbl +/+ mice respectively (Fig. 43A). While in female mice the average of EE 
was 136.61 ± 5.30 and 135.64 ± 7.60 in dark cycle and 124.58 ± 5.33 and 120.88 ± 
5.20 in the light cycle for Cbl -/- and Cbl +/+ mice respectively (Fig. 43C). 
However, both genders of Cbl -/- mice fed a HFD showed a higher EE during the 
dark phase (Fig. 43B, D) compared to Cbl +/+ control mice. The average EE in mice 
fed a HFD was 133.18 ± 4.66 and 127.92 ± 9.01 during dark cycle and 116.03 ± 6.16 
and 116.69 ± 3.18 during light cycle in male Cbl -/- and Cbl +/+ mice respectively (Fig. 
43B). While in female mice the average EE in HFD was 134.63 ± 8.50 and 126.17 ± 
6.89 in the dark cycle and 118.75 ± 9.94 and 119.72 ± 9.25 in the light cycle for Cbl -
/- and Cbl +/+ mice respectively (Fig. 43D). This increase in energy expenditure in Cbl 
-/- mice is due to either nutrient processing and utilization [275, 276] or to the thermic 
effect of food [276, 277]. 
We also measured physical activity of individual mice for a period of 48 hours. 
Analysis of these data revealed that the activity of male Cbl -/- RC mice was 
significantly higher than that of male Cbl +/+ mice (Fig. 44A). However, this difference 
was reduced in male Cbl -/- mice fed a HFD during the light cycle (Fig. 44B). In 
contrast, female Cbl -/- mice had lower activity than Cbl +/+ controls regardless of the 












Fig. 42. Respiratory quotient in Cbl -/- and Cbl +/+ mice (male and female) on RC 
and HFD diet. Values plotted at 1-hour intervals (the average was taken for every 2 
hours from 6 PM to the 4 PM of  the next day). A) male and C) female RC Cbl
 
-/- mice 
and RC Cbl +/+ mice. B) male and D) female HFD Cbl
 
-/- and HFD Cbl +/+ mice 
respectively, male mice n=4, female mice n=3. RQ was increased in male Cbl -/- on RC 
and decreased in female Cbl-/-
 
mice on HFD. Data represent the means ± SEM, Statistical 

































Fig. 43. Energy Expenditure in Cbl -/- and Cbl +/+ mice (male and female) on RC 
and HFD diet. Values plotted at 1-hour intervals (the average was taken for every 2 
hours from 6 PM to the 4 PM of  the next day). A) male and C) female RC Cbl
 
-/- mice 
and RC Cbl +/+ mice. B) male and D) female HFD Cbl
 
-/- and HFD Cbl +/+ mice 
respectively, male mice n=4, female mice n=3.  EE is increased significantly in Cbl -/-. 
Data represent as means ± SEM. Statistical analysis: Multiple t test, * indicates p<0.05; 
















Fig. 44. Activity in Cbl -/- and Cbl +/+ mice (male and female) on RC and HFD diet. 
A) male and C) female RC Cbl
 
-/- mice and RC Cbl +/+ mice. B) male and D) female HFD 
Cbl
 
-/- and HFD Cbl +/+ mice respectively, male mice n=4, female mice n=3. Data 
represent as means ± SEM. Statistical analysis: Two-way ANOVA, Sidak's multiple 
comparisons test,  
 * indicates p<0.05; ** p<0.01; ***p<0.001; ****p<0.0001. 
 
5.4 Adipokine content in the Cbl -/- mice fed a HFD 
Obesity is closely linked to chronic low-grade inflammation resulting from 
macrophage infiltration and activation within adipose tissue, resulting in increased 
released of proinflammatory cytokines. Since Cbl -/- mice maintain insulin 
responsiveness under a HFD, we hypothesized that the release of insulin sensitizing 
adipokines (adiponectin, leptin) is greater whereas pro-inflammatory adipocytokines 
(RBP4, TNF-α and IL6) levels are lower in Cbl -/- compared to Cbl +/+ mice when fed 
a HFD. 
To find out how HFD affects adipokine profile expression in Cbl -/- mice, we 
examined the adipokine profile in WAT, liver and plasma in mice fed a HFD and 
compared it to mice fed a regular chow diet. 
As we previously found in chapter 4 adiponectin levels were slightly higher in the 
WT mice than in Cbl -/- mice. We found that a high fat diet had no impact on 
adiponectin content in WAT and plasma in Cbl -/- and Cbl +/+ mice (Fig. 45A, B). 
However, leptin content was reduced significantly in male Cbl -/- mice fed a HFD 
compared to Cbl +/+ mice on a RC in WAT (Fig. 46A). Similar results were found in 
circulating leptin content in female Cbl -/- on HFD compared to Cbl -/- on a RC diet 
(Fig. 46B).  
RBP4 content in WAT was not different in Cbl -/- mice fed a HFD compared to the 
control Cbl +/+ mice for either gender (Fig. 47A). Also, no change was found in the 
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expression of RBP4 in plasma for either gender fed RC or HFD diets (Fig. 47C). 
However, RBP4 abundance in liver was decreased in female Cbl -/- mice fed a HFD 
compared to female Cbl +/+ mice on the same diet (Fig. 47B).  
We also examined the content of IL-6 and TNF-α in WAT and plasma. We found 
that IL-6 content was no different in WAT or plasma in Cbl -/- mice compared to 
control Cbl +/+ littermates (Fig. 48A, C) and no change was observed in TNF-α protein 























Fig. 45. Expression of adiponectin in WAT and plasma in Cbl -/- and Cbl +/+ on 
HFD and RC diet. No change in the expression of  adiponectin in WAT and plasma of  
mice fed either a HFD or RC diet A) Adiponectin levels in white adipose tissue. B) 
Adiponectin expression in plasma. (RC Cbl -/- male n= 3, HFD Cbl -/- male n=3, RC Cbl 
-/- female n= 3, HFD Cbl -/- female n=3, RC Cbl +/+ male n=7, HFD Cbl +/+male n= 9, 
RC Cbl +/+ female n=3, HFD Cbl +/+ female n=3). Data represent means ± SE. Statistical 






Fig. 46. Expression of  leptin in WAT and plasma in Cbl -/- and Cbl +/+ mice fed a 
HFD or RC diet. Leptin content in WAT in male and female circulating leptin of  HFD 
Cbl -/- was significantly reduced. A) Leptin expressed in white adipose tissue. B) Leptin 
expression in in plasma. (RC Cbl -/- male n= 3, HFD Cbl -/- male n=3, RC Cbl -/- female 
n= 3, HFD Cbl -/- female n=3, RC Cbl +/+ male n=7, HFD Cbl +/+male n= 9, RC Cbl +/+ 
female n=3, HFD Cbl +/+ female n=3). Data represent means ± SE. Statistical analysis: 












Fig. 47. Expression of RBP4 in WAT, liver and plasma in Cbl -/- and Cbl +/+ on 
HFD and RC diet. RBP4 abundance in liver of female Cbl -/- fed a HFD was reduced. 
A) RBP4 levels in white adipose tissue. B) RBP4 expression in Liver. C) RBP4 expression 
in plasma. (RC Cbl -/- male n= 3, HFD Cbl -/- male n=3, RC Cbl -/- female n= 3, HFD Cbl 
-/- female n=3, RC Cbl +/+ male n=7, HFD Cbl +/+male n= 9, RC Cbl +/+ female n=3, 
HFD Cbl +/+ female n=3). Data represent means ± SEM. Statistical analysis: ANOVA-one 



























Fig. 48. Expression of  IL-6 in WAT and plasma, and TNF-α in WAT in Cbl -/- and 
Cbl +/+ on HFD and RC diet. No changes in the expression of  IL-6 or TNF-α in white 
adipose tissue or plasma in Cbl -/- fed a HFD or RC diet A) IL-6 levels in white adipose 
tissue. B) IL-6 levels in plasma. C) TNF-α levels in white adipose tissue. (male and female 
RC Cbl -/- n=5, HFD Cbl -/- n=5, male and females RC Cbl +/+ n=8 RC, HFD=11). Data 













In this chapter, we hypothesized that Cbl -/- mice would adapt differently to the 
metabolic challenges imposed by a high fat feeding. Thus, we evaluated how a HFD 
diet affected insulin sensitivity, substrate utilization (RQ, and EE) and activity and 
WAT adipokine expression in Cbl -/- mice and compared to control Cbl +/+ mice. We 
showed that exposure to a HFD resulted in persistent body weight gain in Cbl -/- mice 
which was inconsistent with previous findings by Molero et al. [18]. However, food 
intake was not significantly different in Cbl -/- mice fed a HFD compared to control 
wild type mice on the same diet and these data are in disagreement with those of 
Molero et al.  [18, 22] who detected a significant increase in food intake in Cbl -/- mice. 
In vivo insulin sensitivity and glucose clearance was increased in Cbl -/- mice fed a 
HFD compared with control Cbl +/+ animals fed the same diet in agreement with the 
previous study [18] where Cbl -/- mice (Jvs 129 x C57BL6) fed a HFD displayed a 
significantly better glucose tolerance compared to wild type control.  
Several factors may account for the differences observed (weight gain, food intake, 
adipocytes cells size and adipokine expression) in our results compared to Molero et 
al. studies [18, 22]. These include: 1) the different genetic background of the mice 
(C57BL6 vs JVS129); 2) we started our experiments at a younger age (at weeks 4 post-
weaning) compared to 20 weeks of age; 3) the duration of the diet intervention for 8 
weeks vs 16 weeks [22];  and 4) the severity of the fat content in the diet, we used 45% 
of HFD, as previous studies [270, 271] while Molero et al. used 60% HFD [18, 201]. 
These factors, likely contributed to these differences between our observations and 
those of Molero et al. [18, 22]. 
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The increase in food intake observed in male Cbl -/- mice with approximately less 
body weight gain and decreased triglyceride content in RC Cbl -/- mice, suggested that 
these mice may have increased energy expenditure and activity. 
In terms of ambulatory activity, we observed a significant increase in activity in 
Cbl -/- male but not female mice, while male and female HFD Cbl -/- mice displayed a 
reduction in the activity during the light cycle compared to their controls (Fig. 44). 
These findings disagree with those of Molero et al. [18], who observed that ambulatory 
activity was increased in HFD Cbl -/- mice compared to wild type during both day and 
night phases of the cycle.  
Our RQ and EE analyses revealed that RQ was higher in male Cbl -/- mice 
compared to control Cbl +/+ mice, pointing to increased carbohydrate oxidation relative 
to lipid oxidation in these animals, while the mice were fed a regular chow diet, and 
no further differences were observed when mice were fed a HFD. Moreover, energy 
expenditure was increased in RC male Cbl -/- mice during light and dark cycle 
compared to male RC Cbl +/+ mice (Fig. 43A). In addition, EE during the dark cycle 
was higher in male Cbl -/- mice fed a HFD compared to control male Cbl +/+ mice fed 
the same diet (Fig. 43B).  
However, RQ was lower in female Cbl -/- mice fed a HFD during both dark and 
light cycle compared to female Cbl +/+ control mice, indicating increased fat oxidation 
(Fig. 42B). RQ was closer to 1.0 on RC diet and it was reduced to approximately 0.85 
in female Cbl -/- mice fed a HFD (Fig. 42D). This suggested that the metabolism 
switched from carbohydrates (CHO) to lipid utilization as a source of energy. While 
energy expenditure was only increased in RC female Cbl -/- during the light cycle 
compared to RC female Cbl +/+ (Fig. 43C). On the other hand, EE in female Cbl -/- mice 
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fed a HFD during the dark cycle was higher compared to their control female Cbl +/+ 
mice fed the same diet (Fig. 43D). 
Our results were consistent with Molero et al. [18] results, who proposed that the 
increase in energy expenditure is the main cause of reducing fat stores in Cbl -/- mice. 
Molero and coworkers found a significant increase in the activity of fatty acid 
oxidation enzymes in skeletal muscle in Cbl -/- mice  [18]. However, we did not 
determine these in our mouse model. We conclude that as a consequence of decreased 
fat stores, Cbl -/- mice are protected against the deleterious effects of excess fat on 
insulin signal transduction that has been detected previously in both humans and 
rodents [39, 278-280]. It is established that enhanced energy expenditure as a result of 
improved insulin action leads to reduced fat accumulation [281, 282]. Consistent with 
this, some mouse models, such as APS- or Grb14-deficient mice or mice expressing 
reduced levels of the regulatory subunits of phosphatidylinositol 3-kinase, exhibit 
improved insulin action and/or signal transduction without any related change in 
adipose mass [283-285]. It was reported by Molero et al. [18] that the increase in 
insulin action is unlikely to be upregulated by increased energy expenditure, because 
the HFD Cbl -/- mice in the previous study [18] had similar glucose tolerance, insulin 
action and fat content to that in the RC Cbl +/+ mice [22] that consume much more 
calories to support their increased energy expenditure. Therefore, they concluded [18] 
that the reduction in lipid accumulation as a result of the increased energy expenditure 
is the main contributor to improved insulin action in Cbl -/- mice fed a HFD. That was 
consistent with our finding that male Cbl -/- increased glucose tolerance and EE in both 
RC and HFD, with reduction in triglyceride content in Cbl -/- fed a RC diet. 
To help explain the role of adipose tissue in the enhanced insulin sensitivity of this 
model we sought to determine the adipokine profile in the mice fed a high fat diet. In 
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this study, leptin content was reduced significantly WAT of male Cbl -/- and also in 
plasma of the female Cbl -/- mice after exposure to HFD, while no significant changes 
in adiponectin or RBP4 abundance were detected in WAT or plasma in mice fed a 
HFD. Compatible with our findings, van der Heijden et al. [286] observed that leptin 
levels were significantly reduced with prolonged HFD-feeding (±30 weeks of HFD-
feeding) although body weight remained high. Leptin levels also declined in mice fed 
the LFD, suggesting an age-related decline in circulating leptin [286]. It has previously 
been found in rodents [287] and humans [288] that circulating leptin levels decline 
with age. However, in contrast to our finding, Ahren et al. [242] reported that plasma 
leptin content in C57BL/6J mice was increased with HFD or as a result of aging as it 
correlated with fat content, body weight and plasma insulin levels. Indeed, as 
adipocytes expand due to enhanced triglyceride storage, leptin secretion increases 
proportionately [289]. Whereas, Kamohara et al. [290] reported that leptin has anti-
diabetic effects independent of its regulation of body weight and energy intake [290]. 
The effects of leptin are mediated by activating the PI3K/AKT pathway that stimulates 
insulin sensitivity in peripheral tissues [291]. 
In contrast to our results, Barnea et al. [292] found that mice fed a HFD with higher 
body weight had lower adiponectin mRNA and protein content in AT than control 
mice without a reduction of adiponectin plasma levels. Also, another study [293], 
reported that adiponectin expression in WAT was reduced after HF dietary 
supplementation in mice. While, Ouchi et al. [51] reported that adiponectin gene 
expression in AT was decreased in obesity with a decrease in adiponectin plasma level 
in humans and rodents [51, 293]. On the other hand, in support of our findings, Peake 
et al. [294] showed that in normal and diabetic subjects, a fat meal challenge did not 
lead to significant changes in adiponectin levels in the circulation [294]. This 
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association between obesity and decreased adiponectin expression is suspected to be 
linked to the increased inflammatory status of AT [295].  
We found no change in RBP4 protein content in WAT and plasma after a high fat 
diet in Cbl -/- mice compared to Cbl +/+ controls. However, RBP4 abundance in liver 
was reduced significantly in female Cbl -/- compared to female Cbl +/+ mice upon 
exposure to a HFD. RBP4 is an adipokine proposed to be a marker insulin resistance 
and type 2 diabetes in human [296]. However, many studies have not been able to 
show this association between human obesity and insulin resistance and have found 
no correlation between BMI and serum and/or adipose tissue mRNA RBP4 levels 
[137]. Kahn and colleagues reported that the development of obesity leads to increased 
expression of RBP4 by adipocytes, influencing metabolic disease development [127, 
265]. Asha et al. [297] reported that high fat diet induced hyperglycaemia in mice, 
which could be partly explained by the RBP4 elevation in circulation, due to its over-
expression, particularly in visceral adipose depots (both retroperitoneal and gonadal 
WAT) [297]. 
In the current study, we found no differences in TNFα or IL-6 in WAT of Cbl -/- 
compared to Cbl +/+ mice for either gender, following an 8-week HFD. van der Heijden 
et al. [286] showed that AT inflammation is associated with the increased secretion of 
TNF-α and leptin to the circulation after 24 weeks of HFD. IL-6 and TNF-α have been 
shown to induce SOCS-3 [119, 298], a protein that was previously thought to interfere 
with cytokine signal transduction but it is also known to inhibit tyrosine 
phosphorylation of the insulin receptor and IRS-1 and causes ubiquitination and 
proteosomal degradation of IRS-1 [299]. This, in turn, diminishes AKT activation that 
normally causes GLUT4 translocation to the plasma membrane [300]. It has been 
found in rodents, that TNF-α is overexpressed in AT from obese animals. Another 
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study reported that the adipocytes of obese patients, including those with morbid 
obesity, overexpressed TNF-α in proportion to the degree of adiposity [301]. On the 
other hand, Matthews et al. [302] demonstrated that deletion of IL-6 (IL6 −/−) in mice 
results in obesity, hepatosteatosis, liver inflammation and insulin resistance when 
animals are maintained on a standard chow diet. However, when IL6−/− mice are 
challenged with HF feeding, inflammation and insulin resistance remain, despite 
equivalent fat mass and ectopic lipid levels in liver relative to control animals [302], 
which indicated that IL-6 is required for protection against hepatic inflammation and 
insulin resistance when mice are challenged with a HFD. 
In this study, no changes were observed in the pro-inflammatory cytokines (TNF-
α and IL-6) in Cbl -/- mice fed a HFD. This might be because of some limitations in 
the HFD diet such as the diet duration was not long enough and/or the composition of 
the diet which contains 45% fat, that may have impacted on the detection of some 
proinflammatory cytokines or observe differences in their (TNF-α and IL-6) protein 
expression levels. 
In conclusion, we determined that Cbl -/- mice on a HFD had a higher EE. Male 
Cbl -/- mice were more insulin sensitive than their control Cbl +/+ mice. Adiponectin 
protein content did not change in Cbl -/- mice. However, leptin content in WAT was 
reduced in male Cbl -/- mice with a reduction in circulating leptin in female Cbl -/- mice. 
RBP4 was reduced in liver of female Cbl -/- compared to the control Cbl +/+ mice. No 
differences were observed in TNFα or IL-6 content in WAT of Cbl -/- compared to Cbl 
+/+ mice for either gender. 
These finding suggests that Cbl -/- (C57BL6 background) mice fed a HFD for 8 
weeks following the post-weaning period, are protected from high-fat-diet induced 
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insulin resistance, consistent with the findings of reported previously by Molero et al. 












































The studies in this thesis highlight the potential effects of c-Cbl depletion in overall 
glucose homeostasis and WAT physiology. The results show that c-Cbl depletion is 
likely to have a role in the regulation of insulin action in adipose tissue mainly through 
the potentiation of insulin mediated ERK signaling and the modulation of adipokine 
expression. In addition, this study is the first to demonstrate a direct effect of the c-Cbl 
pathway in upregulating RBP4 expression in adipose tissue through a ER mediated 









Fig. 49. Hypothetical mechanism of action of c-Cbl depletion in WAT and in 
3T3L1 Cbl KD cells. c-Cbl depletion mediates activation of ERK1/2 by increased 
phosphorylation of ER-α at S118 that leads to upregulated RBP4 expression in WAT of 
female Cbl -/- mice and 3T3L1 Cbl KD cells. Where → = stimulation, Ʇ = inhibition ↑= 





Specifically, we have shown that c-Cbl depletion in C57BL6 mice improves 
insulin sensitivity and changes adipokine expression. We found that RBP4 expression 
in visceral WAT of female Cbl -/- mice was increased locally without affecting RBP4 
protein levels in liver, which is the main site for RBP4 production. However, this was 
not true under a HFD where c-Cbl depletion did not protect against RBP4 production 
in the liver. This finding is supported by a study that reported RBP4 is predominantly 
expressed in the liver in rodents [303]. Thus, the effect of HFD on RBP4 protein 
expression was specific to liver and did not occur in visceral fat. As the liver is the 
major tissue to produce and secrete RBP4, it was predictable that a HFD should 
increase liver RBP4 expression. In addition, however, we suggest that the effect of 
HFD on adipose tissue RBP4 expression and serum RBP4 might be mediated through 
a reduction in adipose tissue inflammation or reduction in visceral fat. This assumption 
was supported by evidence that showed a close connection between RBP4 expression 
and its protein level, and inflammatory markers [137, 304]. Furthermore, our studies 
confirmed that a period of 8 weeks on HFD started at early age and using with 45% 
fat calories, was not a determinant factor for changing inflammatory marker 
expression such as TNF-α and IL-6, which might be induced by longer term HFD. 
On the basis of the current study, we suggest that inhibition or depletion of c-Cbl 
genes in humans might provide a therapeutic approach for prevention/treatment of 






6.2 Pleiotropic effects 
c-Cbl mediated signaling has pleiotropic effects in various cell types and tissues, 
which reflects the c-Cbl protein interactome. Studies in other systems illustrate the 
potential for targeting c-Cbl, although inevitably caution should be applied in 
extrapolating to c-Cbl targets to improve glucose homeostasis.  
The data from the earlier studies [18, 22, 201] suggested that c-Cbl ubiquitin ligase 
activity plays an essential role in the lean phenotype, and may be essential in regulating 
the expression of proteins involved in control of energy expenditure. These studies 
reported that it is c-Cbl ubiquitin ligase activity that plays an important role in the 
regulation of whole-body energy metabolism [201]. An in vivo study in mice by Wu 
et al. [305] showed that generating c-Cbl RING domain inhibitors through modified 
peptides 10, 34, 49 and 51 protected mice from HFD-induced obesity and insulin 
resistance. This research provided several c-Cbl RING domain inhibitors that 
specifically inhibit c-Cbl-UbcH7 binding and could be used to test the efficacy of Cbl 
inhibition in regulation of metabolism. 
In this context it is interesting that Rathinam et al. [306] showed that the E3 
ubiquitin ligase activity of c-Cbl is required to restrict myeloid leukaemia 
development, based on observations in mice with a mutation in the RING finger 
domain of c-Cbl. They noted that myeloproliferative disease (MPD) invariably leads 
to a lethal myeloid leukaemia in the c-Cbl RING finger mutant mouse. In contrast, the 
c-Cbl -/- mouse develops a mild MPD that does not lead to leukaemia. Whether or not 
mutation of c-Cbl is implicated in glucose homeostasis remains largely unexplored. 
Even so, characterization of the perturbations mentioned above provides a direction 
for therapeutics that may aid the treatment of patients with c-Cbl mutations [306]. 
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However, Rush et al. [307] reported that attenuating c-Cbl activity, either through 
RNAi or pharmacological inhibitors ([4-amino-5-(4-methylphenyl)-7-(t-
butyl)pyrazolo-d-3,4-pyrimidine] or PP1) in immortalized human corneal epithelial 
cells (hTCEpi), caused a decrease in receptor ubiquitylation, altered trafficking of the 
ligand-receptor complex, and increase EGFR phosphorylation. Ultimately, these 
biochemical changes culminated in enhanced corneal epithelial wound healing in vitro 
and in vivo. Based on these findings, c-Cbl is a new therapeutic target to increase 
EGFR-activity, which is directly correlates with an increased rate of corneal epithelial 
wound healing. 
In keeping with the pleiotropic role of c-Cbl, Rafiq et al. [308] suggested that c-
Cbl deletion protects the heart against ischemia reperfusion (IR) injury by 
decreasing/preventing ubiquitination and subsequent degradation of EGFR and focal 
adhesion kinase (FAK) and myocyte death. These findings provide evidence for an 
important role of c-Cbl in direct modulation of EGFR and focal adhesion protein 
turnover in the heart. Given that EGFR and FAK signaling downregulation also 
underlie cardiac hypertrophy and other form of heart disease, it is likely that c-Cbl 
plays a role in a variety of stress settings. 
Furthermore, Sévère et al. [309, 310] reported that inhibition of c-Cbl activity 
influence intracellular signaling and promote osteoblast differentiation.   
Taken together the work described on other systems indicates the scope for further 







6.3 Limitations and future work 
A major perceived limitation of this study was the experimental design of the HFD 
study which was not sufficient to produce effects on AT expansion, TG content and 
inflammation (by increasing pro-inflammatory cytokines (IL-6 and TNF-α), and 
macrophage infiltration) causing insulin resistance and T2D. In support of the 
experimental design, it should be noted that others have used a similar protocol [272, 
311]. Nevertheless, it may be the case that we started our study on animals at too early 
an age (post-weaning), that the duration of the HFD was insufficient and that the fat 
content of the diet was insufficient. All these factors may have significant effects on 
adipose tissue metabolism. In follow up studies, animals could be fed a HFD when 
mice are more developed, for example from weeks 8 -16. The duration of the diet 
intervention should be extended to, for example, 16 weeks of age, or it could be started 
later in adult mice. Moreover, the number of calories as fat could be increased to 60% 
instead of 45%. 
Due to the lack of time, the studies here did not explore the impact of c-Cbl 
depletion in brown adipose tissue in detail. In recent years it has become apparent that 
BAT also plays a key role in regulating overall glucose and lipid homeostasis [312, 
313]. Our data suggested that c-Cbl depletion in BAT has no effect in terms of cell 
size and lipid content as no differences were detected in cell size or triglyceride levels 
within BAT. However, to expand these findings we could explore BAT in terms of 
mitochondrial activation that might shed the light on how Cbl -/-  mice increase energy 
expenditure and to see if there is a relation between BAT mitochondrial activation and 
UCP-1 expression or there are some [313] alternative mechanisms.  
Other areas with the potential for future exploration include the determination of 
estrogen levels at different ages throughout the life time of female mice (both Cbl -/- 
147 
 
and Cbl +/+) and to relate these findings to adipokine expression in WAT and in the 
circulation. Potentially this would help explain the gender-differences between males 
and females. 
In addition, further work to examine subcutaneous adipose would be useful, since 
this depot is associated with protection from obesity-related insulin resistance. For 
example, further study could be directed at how c-Cbl depletion influences 
subcutaneous adipose tissue properties, particularly insulin sensitivity and adipokine 
expression compared with visceral fat in Cbl -/- mice. 
 
6.4 Conclusions 
The work in this thesis suggests new ways of understanding the pathogenesis of 
T2D and specifically role of c-Cbl. It is now clear that there are opportunities to 
investigate possible strategies to examine genetic influences of c-Cbl deficiency for 
the prevention or progression of obesity related insulin resistance and T2D in human. 
Augmenting this approach may have therapeutic potential in the management of T2D 
disease in the context of insulin resistance  
This work will be worthwhile not least because it holds promise for new treatments 
by increasing whole-body insulin sensitivity and energy expenditure. In particular, 
there emerges the possibility that c-Cbl depletion could act as a drug target for the 







7.1 Chemical reagents All common chemicals were purchased from Sigma 
Chemical Co., Bio-Rad Laboratories and Life Technologies, unless specified 
below or in the text.  
Bio-Rad Laboratories                   β-mercaptoethanol  
                                                      TEMED (#1610801) 
                                                      Precision plus protein dual color- 
                                                      standards (# 161-0374) 
Sigma                                            Dulbecco’s Modified Eagle Medium (DMEM) 
                                                       DAP solution (# 868272-85-9) 
                                                       Free Glycerol Reagent (# F6428) 
                                                       Insulin solution, human recombinant (#I9278) 
                                                       TRI reagent (#T9424) 
                                                       Chloroform (#C2432) 
                                                       2-propanol (#I9516) 
Trajan Scientific and Medical       DPX mounting medium (# 1.00579.0500) 
Thermo Fisher Scientific               TMB (# 34028) 
                                                       HRP-Conjugated Streptavidin (#N100) 
                                                      Agarose (BP1356)  
                                                      TrackIt 100 bp DNA Ladder (# 10488-058) 
 
7.2 Enzymes and commercially prepared kits 
Roche.com                              Proteinase K (REF 03115887001)  
Promega.com                          GoTaq DNA polymerase (# 9PIM317) 
                                                GoTaq Hot Start Polymerase (# 9PIM500) 
Bio-Rad Laboratories             Bradford Protein Quantification (# 500-0006) 
                                                iScript cDNA synthesis kit (#170-8891) 
Life Technologies                   iTAQ Universal probes supermix (#172-5130) 
Sigma                                      Lipase enzyme (L1754) 
Vector Laboratories                ImmPRESS HRP Anti-Goat IgG Reagent (# MP-7405) 
R&D Systems                         Mouse adipokine array kit (# 607680). 
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7.3 Solutions and buffers  
Solutions used in this thesis are listed below, alphabetically within each section. Final 
concentrations of reagents are given for all solutions.  
 
Buffer 
Tissue lysis buffer for                                         Tris-acetate-EDTA (TAE) buffer    
genotype PCR (pH 8.5)                                               40 mM Tris (pH 7.6) 
100 mM Tris                                                                  5 mM EDTA                                                                                                                            
20 mM acetic acid                                                          1 mM EDTA 
200 mM NaCl                                                             
0.2 % SDS (Sodium Dodecyl Sulfate) 
100 μg/ml proteinase K 
                                                        
                                                                                               
  3T3L1 lysis buffer                                                   Adipose tissue lysis buffer 
       50 mM Hepes                                                            100mM NaCl 
       150 mM NaCl                                                            1mM EDTA 
       10 mM EDTA                                                            1% Triton X-100 
       10 mM sodium pyrophosphate (Na4P2O7)                 50mM NaF 
       10% Glycerol                                                             2mM sodium pyrophosphate 
       2mM sodium vanadate (Na3VO4)                              1mM sodium vanadate 
       100mM NaF                                                               1mM PMSF 
       2µg/ml Pepstatin                                                      2µg/ml Pepstatin                                                          
       2µg/ml Leupeptin                                                     2µg/ml Leupeptin 
       2µg/ml Aprotinin                                                      2µg/ml Aprotinin 
       2mM of Phenylmethylsulfonyl fluoride (PMSF) 
       1% Triton x-100 or 1% NP-40. 
 
    1x PBS buffer (Phosphate-buffered saline, pH 7.4) 
        10 mM Potassium phosphate monobasic (KH2PO4)  
         10 mM Sodium hydrogen phosphate (Na2HPO4)  
         2.7 mM Potassium chloride (KCl)  





1x TBS buffer (pH 7.6)                             1x TBST buffer (pH 7.6) 
 (Tris-buffered saline)                               (Tris-buffered saline, 0.1% Tween 20)                                   
   20 mM Tris base                                             1X TBS buffer 
   150 mM NaCl                                                  0.1% Tween 20 
    distilled water 
                                                                                           
  Tris-EDTA buffer (pH 9.0) 
  10mM Tris-HCl  
  1mM disodium EDTA 
   distilled water          
 
7.4 Electrophoresis Solutions and Western Blotting Solution  
                                            
 Blocking Solution (10 ml)                               3x Laemmli Sample Buffer (LSB)  
 5% non-fat milk powder                                    1 M Tris pH 6.8 (2.4 ml)   
 1x TBST                                                             20% SDS (3ml)  
 5g milk in 100 ml TBST                                    100% Glycerol (3ml)     
                                                                             0.03% Bromophenol Blue (6 mg) 
                                                                             15% β-mercaptoethanol (0.5 ml) 
 
1x Running Buffer pH 8.6                                1x Transfer Buffer pH 8.3 
      25 mM Tris base                                                  25 mM Tris  
      192 mM Glycine                                                  192 mM Glycine 
       0.1% SDS                                                              20% Methanol 
                                                                                      0.1 % SDS 
                                                                                                               
                                                                                                                                       
10 ml of 8% running Gel                                     10 ml of 10% running Gel 
  4.69 ml sterile water (dd H2O)                                3.96 ml dd H2O 
  2.66 ml acrylamide (30%)                                       3.33 ml acrylamide (30%)  
  2.5 ml Tris (1.5 M pH 8.8)                                       2.5 ml Tris (1.5 M pH 8.8)  
  100 μl SDS (10%)                                                       100 μl SDS (10%) 
  100 μl APS (10%)                                                       100 μl APS (10%)  







 10 ml of 12% running Gel 
   3.3 ml dd H2O 
   4 ml acrylamide (30%)  
   2.5 ml Tris (1.5 M pH 8.8) 
   100 μl SDS (10%)  
   100 μl APS (10%)                                                              
   6 μl TEMED. 
                                                             
  5 ml stacking Gel                                                   DNA Agarose Gel (100 ml)                                                                      
     2.98 ml dd H2O                                                      2 gm agarose 
     0.66 ml acrylamide (30%)                                     100 ml TAE                                  
     1.25 ml Tris (1.5 M pH 6.8)                                    2 µl ethidium bromide 
     50 μl SDS (10%)  
     50 μl APS (10%)  
7 μl TEMED                 
       
7.5 Antibodies and primer used in this study are listed in the following tables:  
 
Table 1. Primary antibodies used for western blot. Indicated are the primary 
antibodies used in this study, dilution, species, Cat. No. and source                                         
Primary Antibody Dilution Species Cat. No. Company 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
1:1000 rabbit #9101 Cell Signaling 
Total- p44/42 MAPK 
(Erk1/2) 
1:2000 mouse #9107 Cell Signaling 
Phospho-Akt (Ser473) 1:2000 rabbit #4060 Cell Signaling 
Total- Akt Antibody 1:1000 mouse #2966 Cell Signaling 
UCP1 (C-17): sc-6528 1:1000 goat sc-6528 Santa Cruz 
Phospho-AMPKα (Thr172) 1:1000 rabbit #2531 Cell Signaling 
Cbl (A-9): sc-1651 1:100-
1:1000 
mouse sc-1651 Santa Cruz 
Phospho-IRS-1 (Ser307) 1:1000 rabbit #2381 Cell Signaling 
Anti-β-Tubulin, Clone AA2 1:1000 mouse #T8328 Sigma 
Anti-Actin  1:100 rabbit # A2066 Sigma 




alpha (phospho S118)  
1:1000 rabbit ab31477 Abcam 
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Table 2. Secondary antibodies used for western blot. Indicated are the secondary 
antibodies used in this study, dilution, species, Cat. No. and source. 
 
 
Secondary Antibody Dilution Species Cat. No. Company 
Anti-mouse IgG (H+L) 
(DyLight™ 680 Conjugate) 
1:15000 Donkey #4570 Cell Signaling 
 Anti-rabbit IgG (H+L) 
(DyLight™ 800 4X PEG 
Conjugate) 
1:30000 Rabbit #5151 Cell Signaling 
 
 
Table 3. Antibodies used for ELISA. Indicated are the antibodies used in this study for 
ELISA, species, Cat. No. and source.  
      
               





Antibodies Species Cat. No. Company 
Mouse Adiponectin/Acrp30 mouse DY1119 R&D SYSTEMS 
Mouse Leptin mouse  DY498 R&D SYSTEMS 
Mouse RBP4 mouse DY3476 R&D SYSTEMS 
TNF-α mouse 555268 BD biosciences 
(pharmingen) 
IL-6 mouse 555240 BD biosciences 
(pharmingen) 
Primer                       Sequence Amplicon Reference 
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